Apparatus and methods for maintaining physiological functions

Information

  • Patent Grant
  • 12268878
  • Patent Number
    12,268,878
  • Date Filed
    Thursday, December 16, 2021
    3 years ago
  • Date Issued
    Tuesday, April 8, 2025
    27 days ago
Abstract
A device and algorithm for controlling an autonomic function in an individual. A controller device that utilizes physiological measurements (such as blood pressure) to regulate spinal cord electrical stimulation to stabilize blood pressure. A control interface and algorithm for controlling an autonomic function in a subject. For instance, an algorithm that utilizes physiological measurements (such as blood pressure) to regulate spinal cord electrical stimulation to stabilize blood pressure.
Description
TECHNICAL FIELD

The present disclosure generally relates to the field of bionic interphases. More specifically, the disclosure relates to machine control of physiological functions by way of controlled stimulation (e.g. electrical stimulation). The disclosure has example applications for treating hypotension (low blood pressure) in subjects affected by spinal cord injury.


BACKGROUND

Spinal cord injury (SCI) results in disconnection of some, most, or all descending sympathetic pathways that carry signals responsible for regulating blood pressure. When arterial blood pressure drops or increases following SCI, the spinal cord neurons responsible for blood pressure control no longer have the capacity to maintain blood pressure at a normal physiological level. This disconnection of sympathetic pathways can lead to a situation where blood vessels do not maintain appropriate tone (e.g. the blood vessels can become dilated). As a result, subjects affected by SCI can suffer from extreme hypotension (very low blood pressure). Large amounts of blood may pool in subjects' legs and gut.


Individuals with SCI are often unable to regulate their blood pressure and typically experience a very low arterial blood pressure at rest, during exercise and/or when assuming a seated or standing position. This hypotension can lead to dizziness, disorientation, reduction in cognitive functioning, loss of consciousness and a predisposition to strokes and heart attacks. On the other hand, dangerous elevations in blood pressure (hypertension) can also result from SCI. Hypertension can lead to heart attacks, strokes, and sub-clinical vascular consequences.


Despite widespread misconceptions, autonomic and cardiovascular dysfunctions following SCI are a top health priority (above walking again) and are a main cause of death for individuals with SCI. One primary autonomic issue after high-level SCI (i.e., above the 6th thoracic segment) is orthostatic hypotension, which is clinically-defined as a ≥20 mmHg decrease in systolic blood pressure and/or a 10 mmHg decrease in diastolic blood pressure when assuming the upright posture.


Another critical autonomic issue after SCI is autonomic dysreflexia, which is associated with potentially life threatening elevations in blood pressure due to afferent input activating sympathetic circuitry located caudally on the spinal cord to the location of the SCI. Clinically, autonomic dysreflexia is defined as elevations in systolic blood pressure of 20 mmHg or more.


Currently, the main options for managing blood pressure lability after SCI are pharmacological agents that either can increase or decrease blood pressure. However, most pharmacological tools available for managing orthostatic hypotension and autonomic dysreflexia have significant side effects, as well as a delayed onset of action (at least 10 minutes for drugs to manage high blood pressure, and 60 minutes or more for drugs that manage low blood pressure), and therefore are sub-optimal for managing transient (seconds), but drastic, changes in blood pressure that occur after SCI and other neurological conditions such as multiple sclerosis, autonomic failure, autonomic neuropathy, as well as cancer of the neurological tissue. Importantly, the effects of some of the antihypertensive drugs (e.g. for management of autonomic dysreflexia) can result in a significant decrease in arterial blood pressure, below the desired level, which can last for hours and requires monitoring and further management. As such, pharmacological intervention is often ineffective and can predispose an individual with SCI to extreme changes in blood pressure. Alternative options for controlling blood pressure without the adverse effects inherent to current pharmacological therapies are therefore needed.


The following references provide background to the technology described in the present application:

  • 1. Phillips A A, Krassioukov A V. Contemporary cardiovascular concerns after spinal cord injury: Mechanisms, maladaptations & management. Journal of Neurotrauma. 2015; 32:1927-42.
  • 2. Anderson K D. Targeting recovery: priorities of the spinal cord-injured population. Journal of Neurotrauma. 2004; 21:1371-1383.
  • 3. Wan D, Krassioukov A V. Life-threatening outcomes associated with autonomic dysreflexia: A clinical review. The journal of spinal cord medicine. 2014; 37:2-10.
  • 4. Krassioukov A, Warburton D E, Teasell R, Eng J J. A Systematic Review of the Management of Autonomic Dysreflexia After Spinal Cord Injury. Archives of physical medicine and rehabilitation. 2009; 90:682-695.
  • 5. Krassioukov A, Eng J J, Warburton D E, Teasell R. A systematic review of the management of orthostatic hypotension after spinal cord injury. Arch Phys Med Rehabil. 2009; 90:876-885.
  • 6. Phillips A A, Krassioukov A V, Ainslie P N, Warburton D E R. Perturbed and spontaneous regional cerebral blood flow responses to changes in blood pressure after high level spinal cord injury: the effect of midodrine. Journal of applied physiology (Bethesda, Md: 1985). 2014; 116:645-653.
  • 7. Phillips A A, Warburton D E R, Ainslie P N, Krassioukov A V. Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride. Journal of Cerebral Blood Flow & Metabolism. 2014; 34:794-801.


Patent literature in the general field of the present technology includes:


US20110202107A1 2011 Aug. 18 BLOOD PRESSURE STABILIZATION SYSTEM USING TRANSDERMAL STIMULATION describes electric stimulation apparatus for treating hypotension of patients with spinal cord injury and a method for treating hypotension. The apparatus comprises: a blood pressure measuring means for continuously measuring a blood pressure of a subject; an electric current application means for intermittently applying an electric current to skin of the subject; and a control means for controlling the electric current application means so as to maintain the blood pressure at a predetermined target blood pressure value by activating the electric current application means when the subject blood pressure is equal to or less than the target blood pressure value.


JP2004065529A 2004 Mar. 4 BLOOD PRESSURE CONTROLLING APPARATUS describes a blood pressure controlling apparatus which controls a blood pressure in place of a blood pressure control center of the brain without relying on administration of a hypertensor into a vein or blood transfusion. The apparatus has a blood pressure sensor for detecting a blood pressure value of a living body and an electric stimulation part outputting stimulative electricity to be given to the spinal sympathetic nervous system of the living body. A stimulation frequency control part which calculates the stimulation frequency of a stimulative electricity that needs to be given to the spinal sympathetic nervous system of the living body for raising the blood pressure value of the living body to a target set value. A pulse current output part which outputs the stimulative electricity of the stimulation frequency calculated by the control part.


US20130237948A1 2013 Sep. 12 DEVICES FOR REGULATION OF BLOOD PRESSURE AND HEART RATE describe devices for regulation of blood pressure and heart rate which involve applying electrical treatment signals selected to at least partially block nerve impulses, or in some embodiments, to augment nerve impulses. The apparatus provides a therapy program to provide a downregulating signal to one or more nerves including renal artery, renal nerve, vagus nerve, celiac plexus, splanchnic nerve, cardiac sympathetic nerves, and spinal nerves originating between T10 to L5. In embodiments, the apparatus provides a therapy program to provide an upregulating signal to one or more nerves including a glossopharyngeal nerve and/or a tissue containing baroreceptors.


US20130289650A1 2013 Oct. 31 Neuromodulation for Hypertension Control describes use of neuromodulation for controlling hypertension and other cardiorenal disorders of a patient. A neuromodulation device is configured to be delivered to a patient's body and to apply an electric activation to decrease renal sympathetic hyperactivity of the patient based on monitored blood pressure of the patient, substantially without thermal energization of the patient's body by applying the electric activation. The electric activation may also depend on monitored blood volume of the patient. A feedback control module may be used to provide feedback control information for adjusting the electric activation based on the monitored blood pressure and volume of the patient.


WO2017146659A1 2017 Aug. 31 A SYSTEM FOR DECREASING THE BLOOD PRESSURE describes a blood pressure decreasing system that decreases blood pressure of a patient by non-invasively blocking the sympathetic innervation of the kidney;


US20170056661A1 2017 Mar. 2 METHOD OF REDUCING RENAL HYPERTENSION AND COMPUTER-READABLE MEDIUM describes a method of reducing renal hypertension by applying stimulation to a target zone of an organism using an electronic stimulation device.


US20170007320A1 2017 Jan. 12 RENAL NEUROMODULATION FOR TREATMENT OF PATIENTS and U.S. Pat. No. 9,314,630 B2 2016 Apr. 19 describes a method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve.


U.S. Pat. No. 8,740,825 B2 2014 Jun. 3 Methods and devices for treating hypertension describes devices, systems and methods which control blood pressure and nervous system activity by stimulating baroreceptors and/or nerves to reduce blood pressure.


US20130296965A1 2013 Nov. 7 METHOD FOR BLOOD PRESSURE MODULATION USING ELECTRICAL STIMULATION OF THE CORONARY BARORECEPTORS describes apparatus comprising a first stimulation circuit and a control circuit. The stimulation circuit is configured to be electrically coupled to a first electrode assembly that is configured to deliver electrical sub-myocardial activation stimulation to a coronary baroreceptor from a location within a left atrial appendage of a heart.


There remains a need for apparatus and methods that can help people who are suffering from dysregulated autonomic functions as a result of SCI.


SUMMARY

The present disclosure describes technology that has a number of aspects. These aspects may be applied in combination with one another but may also have individual application. These aspects include, without limitation:


A device and algorithm for controlling an autonomic process in a subject using electrical stimulation. The device and algorithm of the present disclosure are based on the surprising discovery that the electrical excitation of spinal cord circuitry caudal to SCI can control the activity of disconnected sympathetic circuitry to regulate blood pressure.


A method performed by a device for generating control signals for a stimulation device.


Methods for regulating blood pressure in subjects affected by SCI. The methods may be effective to alleviate hypotension in such subjects.


Methods for controlling stimulation delivery devices to generate stimulation that may be effective for controlling one or more autonomic functions in a subject.


A system and methods for controlling one or more autonomic functions in a subject.


A method for medical treatment of a subject affected by SCI.


A device according to an example embodiment comprises a processing unit and circuitry that may be configured such that the device may act as an interface between 1) a physiological monitor (e.g., a blood pressure monitor), and 2) a stimulation device (e.g. an electrical stimulation assembly). The device may interface with a variety of physiological monitors and stimulation devices. The device may optionally be connected wirelessly to either or both of the physiological monitor and the stimulation device.


The device may be configured to receive and analyze information from the physiological monitor. The device may be configured to direct an electrical stimulation assembly to transmit output electrical stimulation (or another type of stimulation device to generate other stimulation). The output electrical stimulation may be epidural, for example. The device may cause the stimulation output to increase or decrease depending on the information received from the physiological monitor. The stimulation output may remain constant depending on the information received from the physiological monitor. The stimulation output may improve control of an autonomic function such as blood pressure. The device may operate by feedback control.


The device may be for use in a subject having dysregulated blood pressure. The dysregulated blood pressure may be due to SCI or other neurological conditions such as multiple sclerosis, autonomic failure, autonomic neuropathy, as well as cancer of the neurological tissue. The output electrical stimulation may raise or lower blood pressure in a subject with dysregulated blood pressure according to a set of predetermined parameters. The output electrical stimulation may be useful for controlling hypotension in a subject affected by dysregulated blood pressure.


Another aspect of the disclosure provides apparatus for controlling blood pressure in a subject. The apparatus comprises an input for receiving a BP signal indicative of a blood pressure measurement and a feedback control circuit connected to receive the BP signal from the input and to deliver a stimulation control signal to an output. The feedback control circuit is configured to: compare the blood pressure measurement to a target blood pressure range, if the comparison indicates that the blood pressure measurement is below the target blood pressure range increase a level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range; and if the comparison indicates that the blood pressure measurement is above the target blood pressure range decrease a level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range.


Another aspect of the disclosure provides a method for operating apparatus to control a subject's blood pressure. The method comprises: receiving at the apparatus a signal containing a blood pressure measurement indicative of the subject's blood pressure and comparing the blood pressure measurement to a predetermined target range stored in a data store accessible to the apparatus If the comparison indicates that the blood pressure measurement is below the target blood pressure range the method increases a level of a stimulation control signal until the blood pressure measurement is in the target blood pressure range. If the comparison indicates that the blood pressure measurement is above the target blood pressure range the method decreases the level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range.


Another aspect of the disclosure provides apparatus for controlling one or more autonomous functions in a subject. The apparatus comprises: an input for receiving a monitor signal indicative of a parameter value and a feedback control circuit connected to receive the monitor signal from the input and to deliver a stimulation control signal to an output. The feedback control circuit is configured to: compare the parameter value to a target range. If the comparison indicates that the parameter value is below the target range the control circuit increases a level of the stimulation control signal until the parameter value is in the target range; and if the comparison indicates that the parameter value is above the target range the control circuit decreases a level of the stimulation control signal until the parameter value is in the target range.


Another aspect of the disclosure provides a method for operating apparatus to control one or more autonomous functions of a subject. The method comprises: receiving at the apparatus a signal containing a monitor measurement indicative of a parameter value; comparing the parameter value to a predetermined target range stored in a data store accessible to the apparatus; and, if the comparison indicates that the parameter value is below the target range increasing a level of a stimulation control signal until the parameter value is in the target parameter value range; and if the comparison indicates that the parameter value is above the target range decreasing the level of the stimulation control signal until the parameter value is in the target range.


Another aspect of the disclosure provides the use of any apparatus as described herein for controlling an autonomic function of a person affected by SCI.


Another aspect of the disclosure provides a method for medical treatment of subjects who have dysfunctional regulation of blood pressure or another autonomic function as a result of SCI (broadly interpreted as any condition which impairs operation of descending sympathetic pathways that normally facilitate control of autonomic functions). The method involves regulating the autonomic function by applying stimulation to structures in the lower back caudal to the SCI. The stimulation may comprise stimulating dorsal roots, dorsal afferent fibres and/or intraspinal structures that are connected directly or indirectly to sympathetic preganglionic neurons that affect the function being controlled.


The stimulation may be provided, for example, in the form of electrical stimulation. The electrical stimulation may be delivered to the dorsal aspect of the spinal cord of the subject, for example by way of an implanted electrode structure. The electrode structure is located caudal to the SCI, for example over the lumbosacral spinal cord segments (e.g. at T11-L1 vertebral levels). The method may involve feedback control of the stimulation based on monitoring a parameter that represents activity of the function being regulated. For example, the function may be blood pressure regulation and the parameter may be a blood pressure measured by a blood pressure monitor.


Further aspects of the disclosure and features and combinations of features of example embodiments are illustrated in the accompanying drawings and described below.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings illustrate non-limiting examples of the present technology.



FIG. 1A is a block diagram illustrating an apparatus according to an example embodiment.



FIG. 1B is a schematic illustration showing a blood pressure control apparatus according to an example implementation.



FIG. 1C is a schematic illustration showing a blood pressure control apparatus according to another example implementation.



FIG. 1D is a block diagram of an example interface device.



FIG. 2A is a flow chart showing an example method for operating an apparatus to control an autonomic function of a subject such as the subject's blood pressure.



FIG. 2B is a flow chart illustrating another example control mechanism with feedback loops to be engaged when blood pressure is either above or below a predetermined target range.



FIGS. 3A to 3G illustrate the restoration of cardiovascular control in individuals with SCI in response to controlled electrical spinal cord stimulation.



FIGS. 4A to 4D illustrate improved cardiovascular function in individuals with SCI that received optimized epidural spinal stimulation.



FIGS. 5A to 5C demonstrate how potentiation of sympathetic circuitry may restore dormant sympathetic cardiovascular pathways.



FIG. 6 illustrates improved integrated cardiovascular responses to orthostatic challenge in an individual resulting from thoracic electrical stimulation.



FIG. 7 illustrates a theoretical framework of transcutaneous stimulation.



FIGS. 8A, 8B, and 8C are graphs respectively illustrating the effect of stimulation to control bladder/bowel function on detrusor pressure (Pdet), floor muscle tone (EMG) and blood pressure (BP)/heart rate (HR).





DETAILED DESCRIPTION

Throughout the following description, specific details are given as examples in an attempt to impart a thorough understanding of the disclosure. However, the disclosure may be practiced in various forms not all of which embody such details. In other instances, well known elements have not been shown or described in detail to avoid unnecessarily obscuring the disclosure. Accordingly, the specification and drawings are to be regarded in an illustrative, rather than a restrictive sense.


One aspect of the present technology provides devices for automated control of a dysregulated autonomic function (such as blood pressure, bladder control and bowel control) in subjects. Such devices have particular application in treating subjects affected by SCI or other neurological conditions such as multiple sclerosis, autonomic failure, autonomic neuropathy, or cancer of the neurological tissue which impair operation of descending sympathetic pathways that normally facilitate control of autonomic functions.



FIG. 1A illustrates an example apparatus 10 according to one embodiment. Apparatus 10 includes a monitor 12 which measures a parameter of an autonomic function of the subject. The parameter may, for example, comprise the subject's blood pressure, bladder volume, bladder pressure, etc. Monitor 12 includes a sensor 12A of a type suitable for the autonomic function being monitored. Sensor 12A may comprise a blood pressure sensor such as a cuff, an arterial pressure sensor, an optical biometric sensor etc. a bladder monitor such as a near infrared sensor (NIRS), an EMG sensor (such as a surface or needle type EMG sensor) for example. An EMG sensor may, for example, be located to measure activity of a muscle such as a muscle that controls the anal sphincter.


Control circuit 14 is configured to receive and analyze information from monitor 12. In the FIG. 1A embodiment control circuit 14 receives a signal indicating the parameter value from monitor 12. The information may comprise, for example, a parameter value such as a diastolic blood pressure, a systolic blood pressure, a diastolic blood pressure and a systolic blood pressure, a blended blood pressure value, a bladder volume, a bladder pressure, a measure of muscle tension or relaxation or the like. Control circuit 14 determines whether the measured parameter value is acceptable, too high or too low. In response to the determination, control circuit 14 controls a stimulation device 16 to apply stimulation to the patient.


The stimulation may be in any of one or more different forms. For example, the stimulation delivered by stimulation device 16 may comprise one or more of:

    • Electrical signals;
    • Optical signals;
    • Magnetic signals;
    • Optogenetic manipulation;
    • Chemogenetic manipulation;
    • Delivery of a chemical agent;
    • Thermal signals; etc.


In some cases the stimulation is delivered to the dorsal aspect of the spinal cord of a subject. The stimulation may affect dorsal roots, dorsal afferent fibres and/or intraspinal structures that are connected directly or indirectly to sympathetic preganglionic neurons that affect the function being controlled. The stimulation may be delivered caudal to a location of an SCI which has interrupted autonomic control of the function. While the inventors do not intend to be bound by any theory of operation, it is thought that stimulation delivered to affect dorsal roots, dorsal afferent fibres and/or intraspinal structures may be processed by neural structures in the spinal cord, particularly structures caudal to the SCI to cause signals on efferent nerves that, in turn, affect operation of the function being controlled.


Control circuit 14 may be integrated with monitor 12 and/or stimulation device 16 or may be provided as a stand-alone device that acts as an interface between monitor 12 and stimulation device 16. Where control circuit 14 is provided as a part of a stand-alone device, the device may comprise a specialized device or a programmed general purpose device such as a stand-alone CPU, microprocessor, mobile phone, tablet, etc.


The following sections provide more detailed example applications of the present technology to the control of blood pressure in subjects affected by SCI. It should be appreciated that all of these examples may be readily adapted for control of another function by replacement of a blood pressure monitor with a monitor that detects a parameter relevant to the function to be controlled and by suitable choice of stimulation. These examples describe electrical stimulation but may be adapted to use other types of stimulation by suitable choice of an alternative stimulation device.



FIG. 1B illustrates a more specific example apparatus 10′. Apparatus 10′ is operable to control blood pressure of a subject. Apparatus 10′ includes a blood pressure monitor 12′ which measures the subject's blood pressure by way of a sensor 12A′, a control circuit 14′ which receives a signal indicating the subject's blood pressure from blood pressure monitor 12′ and determines whether the blood pressure is acceptable, too high or too low.


Control circuit 14′ is configured to receive and analyze information from blood pressure monitor 12′. The information may comprise, for example, a diastolic blood pressure, a systolic blood pressure, or a diastolic blood pressure and a systolic blood pressure. In response to the determination, control circuit 14′ controls a stimulation circuit 16′ to apply signals to the patient by way of electrode(s) 18.


Control circuit 14′ may control any of a wide range of characteristics of electrical signals to be delivered by way of electrodes 18. For example, control circuit 14′ may control one or any combination of: electrical stimulation voltage, the frequency of electrical stimulation, the pulse width of stimulation, the amplitude of stimulation, or any permutation of these factors or other electrical characteristics. The result is that apparatus 10′ delivers electrical stimulation based on information received from the blood pressure monitor.


The signals delivered by control circuit 14 or 14′ may, for example, comprise commands to be executed by a processor or other device in stimulation circuit 16′ and/or parameters to be used by simulation circuit 16′ in generating the stimulation and/or a waveform for stimulation signals in analog or digital form and/or a selection of a program to be used by stimulation circuit 16′ in generating the stimulation.


Control circuit 14 or 14′ may, for example, comprise one or any combination of: a programmed data processor (such as a microprocessor, industrial controller, embedded processor or the like), hardwired logic circuits and/or configurable logic circuits. Control circuit 14 comprises or has access to a data store or data registers which can contain parameters which affect control of the subject's blood pressure.


Embodiments of the disclosure including various designs for control circuit 14 or 14′ may be implemented using any of:

    • specifically designed hardware,
    • configurable hardware,
    • programmable data processors configured by the provision of software (which may optionally comprise “firmware”) capable of executing on the data processors,
    • special purpose computers or data processors that are specifically programmed, configured, or constructed to perform one or more steps in a method as explained in detail herein and/or
    • combinations of two or more of these.


Examples of specifically designed hardware are: logic circuits, application-specific integrated circuits (“ASICs”), large scale integrated circuits (“LSIs”), very large scale integrated circuits (“VLSIs”), and the like. Examples of configurable hardware are: one or more programmable logic devices such as programmable array logic (“PALs”), programmable logic arrays (“PLAs”), and field programmable gate arrays (“FPGAs”)). Examples of programmable data processors are: microprocessors, digital signal processors (“DSPs”), embedded processors, graphics processors, math co-processors, general purpose computers, server computers, cloud computers, mainframe computers, computer workstations, and the like. For example, one or more data processors in a control circuit 14 may implement methods as described herein by executing software instructions in a program memory accessible to the processors.


Processing may be centralized or distributed. Where processing is distributed, information including software and/or data may be kept centrally or distributed. Such information may be exchanged between different functional units by way of a communications network, such as a Local Area Network (LAN), Wide Area Network (WAN), or the Internet, wired or wireless data links, electromagnetic signals, or other data communication channel.



FIG. 1C shows example apparatus 100 in which control circuit 14 is part of a device 102 that acts as an interface between a standalone blood pressure monitor 101 and an electrical stimulation assembly 103. Device 102 may, for example, comprise:


A processing unit


Circuitry which may comprise:

    • 1. A receiving module
    • 2. A transmitting module
    • 3. A feedback control module
    • 4. A memory for storing blood pressure and stimulation settings.



FIG. 1D is a block diagram illustrating a possible construction for device 102. In this example, device 102 comprises a blood pressure receiving interface 102A, a feedback control circuit 102B and a stimulation output interface. Feedback control circuit 102B may have any of a wide variety of constructions. In this example, feedback control circuit 102B comprises a data processor 102D which executes instructions in a program store 102E. The instructions cause the processor to process blood pressure readings received by way of interface 102A and to determine stimulation settings. Parameters may be written to data store 102F, for example, by way of a programmer 102G or remote control/programmer that interfaces to device 102 by way of a wired or wireless data connection. Parameters stored in a data store 102F may be applied in determination of the stimulation settings. The stimulation settings are output to a stimulation system by way of interface 102C.


Device 102 may interface with blood pressure monitor 101 and electrical stimulation assembly 103 in any suitable manner including wirelessly. Interfaces 102A and 102C may, for example, comprise:

    • wireless data interfaces such as WiFi, Bluetooth, or the like;
    • wired or optical data interfaces.


In some embodiments both of interfaces 102A and 102C are provided by the same physical hardware.


Blood pressure monitor 101 may comprise any blood pressure measuring device. For example, blood pressure monitor 101 may be provided by any of:

    • a beat-by-beat finometer device.
    • a device that operates by discrete brachial auscultation methods,
    • a wrist watch with blood pressure measurement circuitry,
    • a phothoplethymography device,
    • a tonometer,
    • an intra-arterial blood pressure measuring cannula.


Electrical stimulation assembly 103 may be provided by any suitable stimulation assembly capable of providing spinal cord electrical stimulation as described herein. For example, electrical stimulation assembly 103 may comprise a commercially-available electrical stimulation device. The electrical stimulation assembly may, for example, provide epidural spinal cord stimulation.


The electrical stimulation assembly may comprise one or more stimulation electrodes 103B connected to an electrical pulse generator 103A. In some embodiments electrodes 130B are provided on an implantable device. The implantable device may, for example, comprise a commercially available electrode paddle. A wide range of suitable implantable electrode structures are commercially available. These electrode structures differ in the number of electrodes provided (configurations which include 8, 16, or 32 electrodes and associated contact leads are common). Such structures may be designed for surgical or percutaneous application and are dimensioned to fit within the dimensions of the spinal canal at the appropriate spinal segment.


Device 102 may be programmed to decide, based on pre-determined criteria, the appropriate stimulation output to be supplied by electrical stimulation assembly 103. The criteria may, for example, include one or more of:

    • one or more parameters that indicate what blood pressure is desirable for a subject;
    • one or more parameters that indicate how the subject responds to stimulation from electrical stimulation assembly 103;
    • one or more parameters that specify characteristics of a stimulation signal (e.g. frequency, current, pulse width, pulse repetition frequency, for an electrical stimulation signal);
    • one or more parameters that affect operation of an algorithm or method executed by device 102 (e.g. an amount to increment a stimulation level when it is desired to increase blood pressure, an amount to decrement a stimulation level when it is desired to decrease blood pressure, a lag time to wait before further adjusting the stimulation level etc.).


The appropriate stimulation output may, for example, be based on a predetermined target blood pressure range for an individual. The target blood pressure range may, for example, be predetermined by a medical professional (e.g. a physician, pharmacist, physician-aid or other trained operator). The target blood pressure range may be predetermined based on the resting blood pressure of the subject prior to stimulation, and/or other criteria as determined by a medical professional. In some embodiments the target blood pressure range is adjustable based upon a user input that allows a medical professional and/or the subject to move the target blood pressure range toward higher or lower blood pressures. The user input may be provided for example using programmer 102G or some other interface that is connected to control device 102.


The appropriate stimulation output may also be based on the comfort and/or safety of the subject. For example, the stimulation output may be selected so that a stimulation level is kept lower than a threshold above which the stimulation becomes uncomfortable to the subject and/or causes side effects such as spasticity.


The appropriate stimulation output may optionally be based on a mode of operation of device 102. For example, device 102 may have a plurality of routines where each routine may specify different parameters. For example, a “Morning sit up stimulation routine” may control for a higher blood pressure than an “afternoon resting routine”. In some embodiments a subject may select among the plurality of routines using programmer 102G or some other interface that is connected to control device 102. In some embodiments, device 102 incorporates a scheduler that automatically selects one of a plurality of routines based on time of day.


The appropriate stimulation output may be expressed as characteristics of one or more electrical stimulation signals to be delivered to the subject. These characteristics may, for example, comprise:

    • an amplitude (e.g. voltage and/or current) of the signal(s),
    • an electrical pulse frequency of the signal(s),
    • a pulse width of stimulation,
    • a polarity of the stimulation,
    • a selection of electrodes for delivery of the stimulation,
    • other electrical characteristics of the signal(s); or
    • any combination/permutation of these factors.



FIG. 2A illustrates an example feedback control/decision making algorithm 200 that may be used in accordance with the present disclosure. Such an algorithm may, for example, be implemented using software instructions 102E. Block 202 receives a stream of blood pressure measurements. For example, blood pressure measurements may be received on the order of a few to a few tens of measurements per minute. Block 204 determines a running average blood pressure that is made available to the rest of method 200. Block 204 may, for example, determine an average blood pressure for an immediately previous period. For example, the average may be determined for a period having a length of a few seconds to a few minutes (e.g. 30 seconds).


Method 200 includes loop 206 which begins by comparing at 208 the current average blood pressure from block 204 to the target range. If the presently measured average blood pressure exceeds the target range then block 210A triggers a reduction of the stimulation level. If the presently measured average blood pressure is within the target range then block 210B holds the stimulation at the current level. If the presently measured average blood pressure is below the target range then block 210C triggers an increase of the stimulation level. Block 212 delays for a short period before the next iteration of loop 206.


An increase or reduction of the stimulation level may be achieved by incrementally increasing or reducing the stimulation level. The increments may be predetermined fixed increments or may be set based on factors such as how far away from the target range is the presently measured blood pressure. In an example embodiment the increment size is increased in proportion to a difference between the presently measured blood pressure and the closest part of the target blood pressure range. Increments for increasing and decreasing the stimulation level may be the same or different. Another way to increase or reduce the stimulation level comprises ramping the stimulation level up or down. The rate(s) at which the stimulation level are ramped up or down may be fixed or variable. In some embodiments the rates of increase and/or decrease are set as a function of a difference between the presently measured blood pressure and the closest part of the target blood pressure range. The rates of increase and/or decrease may be higher when a difference between the presently measured blood pressure and the closest part of the target blood pressure range is larger.



FIG. 2B shows another example of a blood pressure feedback control algorithm 200A that may be executed by a device 102 and/or a feedback circuit 14. Control algorithm 200A may detect whether the measured blood pressure of a subject (220) is within the target range (block 220A) or outside of the target range. If the measured blood pressure of a subject is below the predetermined target range (block 220B) then sub-loop 223 is engaged. In sub-loop 223 the stimulation level supplied by stimulation apparatus 103 is elevated. This may be done, for example, by increasing a voltage and/or current of an electrical stimulation signal and/or by adjusting a frequency of the electrical stimulation signal to a frequency that is more effective for increasing blood pressure. For example, the stimulation voltage or current may be increased incrementally by performing sub-loop 223 until the target blood pressure range is reached.


In some embodiments the stimulation voltage is elevated in increments having sizes in the range of 0.1 V-10 V. The stimulation assembly may be configured, for example, to elevate voltage in 0.5 V increments. The voltage may be elevated incrementally. The voltage increments may be predetermined by a medical professional. The voltage increments may be determined on a per subject basis.


The increments may be selected depending on the type of stimulation assembly used. For example, where an epidural stimulation assembly is used, the electrical stimulation may be elevated in increments in the range of about 0.1V to 30 V (or about 0.4V to about 2.5V). As another example, where a transdermal stimulation assembly is used, the electrical stimulation may be increased by delivering higher currents. For example, electrical current may be elevated in increments in the range of about 0.1 to about 150 mA (in some embodiments, the increments of electrical current are about 20 mA).


If blood pressure does not elevate into the target range in response to an incremental increase in stimulation level, then sub-loop 223 may further increase stimulation voltage at the predetermined increment until a blood pressure within the target blood pressure range is reached or until a maximum stimulation level has been reached. As mentioned above, the maximum stimulation level may be set to preserve the subject's comfort and/or safety.


In some embodiments method 200 stops increases in stimulation level in response to receiving a “STOP” command. The stop command may be issued in response to the subject activating a button or other control, for example.


Blood pressure may not respond instantaneously to excitation of sympathetic preganglionic neurons, and therefore there may be a lag between commanding a change in a stimulation level and a consequential change in the subject's blood pressure. For this reason, method 200 provides a lag duration between a time when a stimulation level is set and a next time at which the stimulation level adjustment. This lag may be on the order of seconds, for example. In some embodiments the lag is at least 10 seconds. The device can operate with a variety of lag durations from 1 second to an hour or more on a per subject basis. For example, the device provides a lag duration in the range of a few seconds to 15 minutes. In some embodiments, the device provides a lag duration of about 10 seconds.


In some embodiments the lag is variable. For example, the lag may be reduced in cases where the presently measured blood pressure is far from the target range and the lag may be increased in cases where the presently measured blood pressure is close to or within the target range.


If a blood pressure within the target range is reached (block 220A), the stimulation level may be maintained until blood pressure deviates from the target range.


If blood pressure is above the upper threshold of the predetermined target range (block 220C) then sub-loop 224 is performed to reduce blood pressure by reducing the stimulation level supplied by stimulation system 103. For example, stimulation voltage and/or current may be reduced. In this manner the stimulation level may be reduced until a blood pressure within the target blood pressure range is reached.


The reduction may be incremental. For example, voltage and/or current increments may be predetermined by a medical professional and may be the same as or different from the increment used in sub loop 223. The increments may be determined on a per subject basis. Stimulation voltage may be reduced in increments in the range of 0.1 V-10 V for example. In some embodiments, stimulation assembly 103 reduces voltage in increments of about 0.5 V each time sub-loop 224 is executed. If a blood pressure within the target range is reached (block 220A), the stimulation intensity may be maintained until blood pressure deviates from the target range.


The stimulation increments may vary depending on the type of stimulation assembly used. For example, where a transdermal stimulation assembly is used, the electrical stimulation may be decreased in increments in the range of about 0.1 mA to about 150 mA (or about 20 mA). Where an epidural stimulation assembly is used, the electrical stimulation may be decreased in increments in the range of about 0.1V to about 30V (or about 0.3V to 2.4V, for example 2V, or about 0.5V).


If blood pressure does not decrease sufficiently in response to an incremental decrease in voltage by sub-loop 224, then stimulation voltage may be further decreased by the predetermined increment until a blood pressure within the target blood pressure range is reached.


Blood pressure may not respond instantaneously to the reduction of excitation of sympathetic preganglionic neurons, and therefore there may be a lag of at least 10 seconds between stimulation and the subsequent blood pressure detection and voltage adjustment. The device can operate with a variety of lag durations from 1 second to several hours on a per subject basis. For instance, the device can operate with a lag duration from a few seconds to 15 minutes. In some embodiments, the device operates with a lag duration of less than about 1 minute, such as a lag duration of about 10 seconds.


In some embodiments, the stimulation output has one or any combination of two or more of the following characteristics:

    • the stimulation output comprises electrical pulses presented at a pulse frequency in the range of about 5 Hz to 10 kHz (or about 30 Hz to about 60 Hz);
    • the stimulation output comprises electrical pulses having a pulse width in the range of about 0.002 seconds to about 20 seconds (or about 0.033 seconds to about 0.17 seconds);
    • the stimulation output has a voltage in the range of about 0.1 V to about 24 V;
    • the stimulation output has a voltage in the range of about 0.1 V to about 500 V;
    • 3a the stimulation output has an amperage in the range of about 0 mA to about 1000 mA.


In some embodiments where the stimulation signals are delivered by way of an epidural stimulator the stimulation output has a voltage in the range of about 0.1 V to about 20 V and an amperage in the range of about 0 mA to about 100 mA.


In some embodiments where the stimulation signals are delivered by way of a transcutaneous stimulator the stimulation output has a voltage in the range of about 0.1 V to about 100 V and an amperage in the range of about 0 mA to about 100 mA.


In accordance with one aspect of the disclosure, the device may be used to control blood pressure in a subject with dysregulated blood pressure. The dysregulated blood pressure may be due to SCI or other neurological conditions including, but not limited to, multiple sclerosis, autonomic failure, autonomic neuropathy, as well as cancer of the neurological tissue. The device may be used to control blood pressure in a subject with SCI. In one aspect of the disclosure, the device may control electrical stimulation of the spinal cord. Electrical stimulation of the spinal cord may be performed caudal to injury. Electrical stimulation of the spinal cord may be performed at spinal segments T1-L1, as well as anywhere over the thoracic segment where sympathetic preganglionic neurons are stimulated to elicit a blood pressure effect.


Methods and apparatus as described herein may be applied in combination with pharmacological agents that affect blood pressure. For example, methods and apparatus as described herein may be applied to a subject who is being treated with a pharmacological agent for increasing blood pressure. The use of the present apparatus and methods may reduce the dosage of the pharmacological agent required and/or the time between doses of the pharmacological agent. This may reduce side effects of the pharmacological agent in some cases. Further, use of the present apparatus and methods may maintain control over blood pressure during the time required for a dose of the pharmacological agent to take effect.


The present disclosure may be applied to control autonomic functions other than blood pressure. For example, apparatus and control algorithms as described herein may be applied for controlling a variety of autonomic processes in a subject using electrical or other stimulation. Autonomic processes may include regulation of blood pressure, bladder/bowel control, sexual function, etc.


A device comprising a circuit 14 as described herein may receive input from any of a variety of physiological monitors and control a variety of electrical stimulation assemblies in response to the inputs. Such a device may be configured to receive information from the physiological monitor, and analyze such information based on a control algorithm as described above for example. The device may be configured to direct the electrical stimulation assembly to transmit output electrical stimulation based on the control algorithm. The output electrical stimulation may be transdermal or epidural. In some embodiments, epidural delivery of electrical stimulation is used. The stimulation output may increase or decrease depending on the information received from the physiological monitor. The stimulation output may remain constant depending on the information received from the physiological monitor. The stimulation output may improve control of any of a range of autonomic functions. The control interface may operate by feedback control.


For example, epidural spinal cord stimulation as described may be applied to acutely modulate bladder and/or bowel function in subjects affected by SCI. This may be done by providing a program to deliver stimulation that facilitates urination and/or bowel function and providing an interface that allows a subject to input a command to perform the program. The program may specify a type of stimulation that is specific to bladder/bowel control and that does not significantly affect blood pressure or other functions. A device as described herein may be configured to temporarily suspend active control over BP while performing a bowel/bladder control program and/or the bladder/bowel control program may be performed in parallel with control of blood pressure or other autonomous functions as described herein.


For example, in an example case a program that involved applying electrical stimulation comprising a pulse width 450 ms, a frequency of 45 Hz, and an intensity of 6V for a stimulation time of 105 s led to an increase in external anal sphincter/pelvic floor muscle tone (as measured by EMG) and detrusor pressure (Pdet). This stimulation was found to reduce the time required for bowel evacuation from 117 to 23 minutes (i.e. >80%). The stimulation was applied using a subset of the electrodes provided by an implanted 16-electrode array (Specify 5-6-5, Medtronic, Minneapolis, MN, USA) placed at the T11-L1 vertebral levels and driven by a neurostimulator (RestoreAdvanced SureScan™ MRI neurostimulator). The subset of electrodes was selected to affect bladder/bowel function.



FIGS. 8A to 8C show that the stimulation led to an increase in external anal sphincter/pelvic floor muscle tone (EMG) and detrusor pressure (Pdet). Blood pressure (BP) and heart rate (HR) remained stable during stimulation. Dashed lines indicate start and stop of stimulation.


In some embodiments blood pressure monitor 101 is replaced with a monitor for measuring urinary bladder/bowel volume. In such embodiments a measured bladder volume may be processed to alter signals delivered to control bowel/bladder function.


Without committing to any particular theory of operation, it is thought that stimulation delivered by way of such electrodes may activate sympathetic and/or parasympathetic spinal neuronal structures in the lower part of the spinal cord to cause changes of functions in blood vessels, bladder, bowel and/or sexual organs. The neuronal structures involved may be located within the T11 to S5 segments of the spinal cord, for example. Stimulation may be configured to control a particular function by selecting electrodes and/or the nature of the stimulation.


The desired structures may be stimulated transdermally. Transdermal stimulation may incidentally also activate afferent fibres in skin/underlying tissue.


Blood pressure or another function may be controlled by electronic feedback control. This may be done by monitoring one or more parameters that indicate activity of the function being controlled and setting a level of the stimulation based on the monitored parameters. In the case of blood pressure the monitored function may be blood pressure itself (measured using any available blood pressure monitoring modality). The stimulation level may be controlled to keep blood pressure within a target range. Such stimulation may be particularly useful for raising blood pressure to counteract the extreme hypotension that often accompanies SCI.


In some embodiments the method involves administering to the subject pharmacological agents that have the effect of raising blood pressure and adjusting the stimulation level automatically to maintain the desired blood pressure taking into account the effect of the pharmacological agent. This control may cause the stimulation level to be higher in the period before the pharmacological agent takes full effect. The stimulation level may be lower (or off) when the pharmacological agent is fully effective. The stimulation level may then increase as the pharmacological agent is metabolized or excreted or otherwise ceases to maintain blood pressure.


In some embodiments the method may comprise selection of a program for control of an autonomic function. Different programs may be provided for the same autonomic function. Different programs may differ, for example, in one or more of:

    • Target level for the function (e.g. target blood pressure range);
    • Lag time for control (e.g. time constant for feedback);
    • Rate of increase or decrease of stimulation level;
    • Maximum allowed stimulation level etc.


A program may be selected from among a plurality of programs in response to user input by way of a suitable control, an automatic scheduler and/or the like. Where the stimulation is delivered by way of apparatus as described herein, programs may be defined by stored data which may be resident in a control circuit (e.g. 102) or a stimulator (e.g. 103) or a device which combines these functions, for example.


In some embodiments, the method may include control of plural autonomic functions. For example, the method may involve controlling blood pressure and also controlling bladder/bowel function. In such cases, different stimulation may be provided for each of the autonomic functions. The stimulation for the different functions may be selected in such a manner that the stimulation associated with one function does not significantly affect another function. This may be achieved, for example, in the case of electrical stimulation, by one or more of:

    • using different combinations of electrodes for stimulation of the different functions;
    • using different polarities of stimulation;
    • using different frequencies, waveforms or other stimulation signal characteristics for the different functions etc.


Control of the bladder/bowel function may be applied selectively to assist a subject with urination and/or bowel voiding. Where this is done in combination with control over blood pressure the stimulation for blood pressure control may be performed concurrently with stimulation of bowel/bladder function or the stimulation for blood pressure control may be temporarily interrupted while applying stimulation for bowel/bladder function.


Stimulation for sexual function may be handled in the same or a similar way to stimulation for bowel/bladder function.


EXAMPLES

Prototype embodiments of systems as described herein have been tested on a number of subjects in a study that was approved by the clinical research ethics board of the University of Louisville, the University of California Los Angeles, and the University of British Columbia. Each of the subjects presented with motor, sensory, and autonomic completeness of injury. Each of the subjects provided written informed consent. All subjects of the study were:

    • screened for the presence of orthostatic intolerance and exhibited a reduction in systolic arterial blood pressure of at least 20 mmHg in response to a sit-up test;
    • assessed for neurological level and completeness of injury according to standard guidelines.


      Epidural Electrical Spinal Stimulation


An epidural spinal cord stimulation unit (RestoreADVANCED™, Medtronic, Minneapolis, MN, USA) in combination with a 16-electrode array paddle 301 (see FIGS. 3A to 3G). Paddle 301 was a 5-6-5 paddle from, Medtronic, Minneapolis, MN, USA. Paddle 301 was implanted at T11-L1 vertebral levels over the lumbosacral spinal cord segments. 1 During the implantation surgery, the electrode array was positioned over the midline of the exposed dura and its location was assessed intraoperatively with thresholds and amplitudes of electromyography (EMG) recorded from leg muscles elicited by stimulation at 2 Hz. Two wide-field stimulation configurations, where the anodes where located at the most rostral three locations on the electrode, and the cathodes were located at the most caudal three portions of the electrode, (or vice versa) were used for stimulating and eliciting these effects.


General Integrated Hemodynamic Assessment Approach


At least one month after implantation surgery, and following the development of a cardiovascular optimized stimulation paradigm (CV-scES); i.e., elucidating the optimum stimulation parameters that could modulate blood pressure) as shown at 201, we conducted a within person trial to investigate the immediate cardiovascular effects of CV-scES. The three participants were randomized to receive either stim-on or stim-off condition first and the two testing sessions were separated by no more than 24 hours.



FIG. 3A includes beat-by-beat blood pressure via finger photoplethysmography (Finometer PRO™, Finapres Medicine Systems, Amsterdam, Netherlands) corrected to brachial pressure (Dinamap, General Electric Pro 300V2; Tampa, Florida, USA), electrocardiogram, central sympathetic outflow via sympathetic skin responses, cardiac function via echocardiography (Phillips EPIQ7™, Philips Medical System, Andover, MA, USA), and neurovascular coupling by insonating the middle and posterior cerebral arteries with a transcranial Doppler (ST3 Transcranial Doppler™, Spencer Technologies, Redmond, WA, USA). During the sit-up position only, we also assessed executive function (i.e., verbal fluency), as well as attention/concentration (Stroop test; FIGS. 4A and 4C Part 306). All procedures were assessed in the supine position and then in response to sit-up with and without stimulation.


Example 1: Restoration of Integrated Cardiovascular Control in Response to Epidural Stimulation


FIG. 3A illustrates the cardiovascular response of an individual following controlled electrical stimulation. All panels show raw cardiovascular data for one study participant. Parts 304 and 302 in FIG. 3B show the participant's acute blood pressure responses to increases and decreases in voltage where blood pressure is accurately controlled and regulated by titration of stimulation up and down, and subsequent increases in voltage lead to further increase in blood pressure. Part 302 shows that acute reductions in voltage can reduce blood pressure in a controlled and incremental way.


Raw blood pressure traces 302 indicate that when the stimulator was activated there was an immediate reversal of orthostatic hypotension that was achieved in a controlled manner by gradually increasing voltage. Orthostatic hypotension prevailed again when the stimulator was turned off, demonstrating a capability to dynamically modulate blood pressure. Under steady state conditions, the stimulator was able to offset chronic hypotension by increasing and maintaining blood pressure approximately 20 mmHg above resting baseline, and increased low-frequency oscillations in systolic blood pressure indicating a return of medullary cardiovascular control.


Raw echocardiography imaging 303 in FIG. 3C of the left-ventricular outflow tract in the seated position demonstrates that peak outflow velocity and cardiac output are increased with stimulation.


Model-flow estimations 307 of mean arterial blood pressure, stroke volume, heart rate and systemic vascular resistance obtained from finger plethysmography along with raw transcranial Doppler images of the mid cerebral artery (MCA) and the posterior cerebral artery (PCA). Note the stepwise increase in all variables when the stimulator was activated (V), except heart rate which was offset due to the associated increase in stroke volume.


Raw changes in PCA velocity in response to cerebral activation (eyes open) 305 indicate the complete restoration of neurovascular coupling with stimulation (i.e., appropriate regulation of PCA velocity with cerebral activation). Lower-limb electromyography responses 305 to both low-frequency ‘motor-optimized’ and high-frequency ‘cardiovascular-optimized’ epidural stimulation reveal no concurrent motor activity during CV-optimized stimulation.


Example 2: Cardiovascular Optimized Epidural Stimulation Improved Multiple Facets of Cardiovascular Function in all Three Study Participants


FIG. 4A illustrates the improvements to cardiovascular function following controlled electrical stimulation in individuals with SCI. FIGS. 4B to 4D are enlarged views of portions of FIG. 4A. FIG. 4B shows Systolic blood pressure (SBP), posterior cerebral artery velocity (PCA), and mid cerebral artery (MCA) velocity were all maintained with stimulation in response to a 10 minute sit-up test. Stimulation increased low-frequency oscillations in SBP while in the seated position, indicating a return of supraspinal cardiovascular control. FIG. 4A (top right) shows changes in posterior cerebral artery blood flow in response to neural activation using a classical eyes-closed eyes-open task indicate that stimulation restored neurovascular coupling in all individuals (i.e., there was an appropriate increase in PCA flow in response to neural activation with stimulation), which was virtually absent without stimulation. FIG. 4D shows: echocardiography-derived cardiac responses to orthostatic challenge indicate that stimulation prevented the decline in end-diastolic volume (EDV), stroke volume (SV) and cardiac output (CO) noted without stimulation; consequently, there was also a reduction in the magnitude of orthostatic-induced tachycardia with stimulation. Also shown are the group mean±SD for the major cardiac variables summarized in panel.


Example 3: Theoretical Restoration of Dormant Supraspinal Descending Sympathetic Cardiovascular Pathways Through Potentiation of Caudal Sympathetic Circuitry


FIGS. 5A to 5C show how cardiovascular functioning may be restored in individuals with SCI following controlled electrical stimulation. FIG. 5A shows descending sympathetic pathways from the rostral ventrolateral medulla (RVLM) in an intact spinal cord may lead to efficacious action potentials (i.e., depolarization) in sympathetic circuitry that allow for supraspinal control over vascular tone (i.e., vasoconstriction) and blood pressure. FIG. 5B shows how interrupted descending sympathetic pathways due to an anatomically discomplete SCI, where a small number of preserved descending sympathetic fibres crossing the site of injury are not capable of eliciting action potentials in sympathetic circuitry caudal to injury. FIG. 5C illustrates that epidural spinal electrical stimulation increases the resting membrane potential of sympathetic circuity caudal to the spinal cord injury allowing for the previously non-efficacious preserved descending sympathetic fibres crossing the site of injury to actively regulate caudal sympathetic circuits, and thereby restore supraspinal control of vascular tone and blood pressure. As shown in FIG. 7, epidural electrical stimulation may stimulate dorsal afferents that likely affect the membrane potential of intersegmental and intrasegmental neurons, that: 1) receive direct input from descending sympathetic pathways, and 2) directly and indirectly lead to depolarization of sympathetic preganglionic neurons leading to regulation of vascular tone.


Example 4: Thoracic Electrical Transcutaneous Stimulation Improved Integrated Cardiovascular Responses to Orthostatic Challenge


FIG. 6 shows improvements to cardiovascular function following controlled transcutaneous electrical stimulation in an individual with SCI. Participant: Female, 32 years of age, spinal cord injury at C6 (AIS-A), injured August 2009. Left Inlet: Although suffering from severe orthostatic hypotension when assuming upright posture, electrical stimulation at the TVII level restored blood pressure, cerebral blood flow, cardiac function, and symptoms of orthostatic intolerance to supine levels. Note: Increasing current (from 20 mA, to 40 mA, to 50 mA) resulted in step-wise increases in cardiovascular function. Right Inlet: electromyography recording of lower-limbs shows that skeletal muscle contraction was not activating the skeletal muscle pump of the venous vasculature, indicating that excitation of sympathetic preganglionic neurons was responsible for the cardiovascular restoration. Note: Without stimulation self-reported symptoms of presyncope were severe, being between 6-9, while with stimulation symptoms were completely abrogated. Participant reported that cognitive processing was so slow in the upright position that she was “not conversational” until the stimulation was turned on.


Example 5: Theoretical Framework of Transcutaneous Stimulation


FIG. 7 shows how thoracic level stimulation using transcutaneous electrical stimulation excites dorsal afferents that likely excite intersegmental and intrasegmental neurons, which directly and indirectly lead to depolarization of sympathetic preganglionic neurons leading to increased vascular tone.


Interpretation of Terms

Unless the context clearly requires otherwise, throughout the description and the claims:

    • “comprise”, “comprising”, and the like are to be construed in an inclusive sense, as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”;
    • “connected”, “coupled”, or any variant thereof, means any connection or coupling, either direct or indirect, between two or more elements; the coupling or connection between the elements can be physical, logical, or a combination thereof;
    • “herein”, “above”, “below”, and words of similar import, when used to describe this specification, shall refer to this specification as a whole, and not to any particular portions of this specification;
    • “or”, in reference to a list of two or more items, covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list;
    • the singular forms “a”, “an”, and “the” also include the meaning of any appropriate plural forms.


Words that indicate directions such as “vertical”, “transverse”, “horizontal”, “upward”, “downward”, “forward”, “backward”, “inward”, “outward”, “vertical”, “transverse”, “left”, “right”, “front”, “back”, “top”, “bottom”, “below”, “above”, “under”, and the like, used in this description and any accompanying claims (where present), depend on the specific orientation of the apparatus described and illustrated. The subject matter described herein may assume various alternative orientations. Accordingly, these directional terms are not strictly defined and should not be interpreted narrowly.


The following abbreviations have the following meanings:

    • BP, blood pressure.
    • CG, celiac ganglia
    • CO, cardiac output.
    • DBP, diastolic blood pressure.
    • dP/dt, delta pressure over delta time (cardiac contractility).
    • EDV end-diastolic volume.
    • HR, heart rate.
    • IMG, inferior mesenteric ganglia.
    • MCA mid cerebral artery.
    • MH, medial hamstring.
    • PCA, posterior cerebral artery.
    • PCAvmean, mean flow velocity for PCA.
    • RVLM, rostral ventrolateral medulla.
    • SBP, systolic blood pressure.
    • SCG, superior cervical ganglia.
    • SCI, spinal cord injury.
    • SG, stellate ganglia.
    • SMG, superior mesenteric ganglia.
    • SOL, soleus.
    • SV, stroke volume.
    • TA, tibialis anterior.
    • VL, vastus lateralis.
    • vmean, mean flow velocity.


The disclosure may also be provided in the form of a program product. The program product may comprise any non-transitory medium which carries a set of computer-readable instructions which, when executed by a data processor, cause the data processor to execute a method of the disclosure (e.g. a method as illustrated in FIG. 2A or FIG. 2B). Program products according to the disclosure may be in any of a wide variety of forms. The program product may comprise, for example, non-transitory media such as magnetic data storage media including floppy diskettes, hard disk drives, optical data storage media including CD ROMs, DVDs, electronic data storage media including ROMs, flash RAM, EPROMs, hardwired or preprogrammed chips (e.g., EEPROM semiconductor chips), nanotechnology memory, or the like. The computer-readable signals on the program product may optionally be compressed or encrypted.


In some embodiments, the disclosure may be implemented in software. For greater clarity, “software” includes any instructions executed on a processor, and may include (but is not limited to) firmware, resident software, microcode, and the like. Both processing hardware and software may be centralized or distributed (or a combination thereof), in whole or in part, as known to those skilled in the art. For example, software and other modules may be accessible via local memory, via a network, via a browser or other application in a distributed computing context, or via other means suitable for the purposes described above.


Where a component (e.g. a software module, processor, assembly, device, circuit, etc.) is referred to above, unless otherwise indicated, reference to that component (including a reference to a “means”) should be interpreted as including as equivalents of that component any component which performs the function of the described component (i.e., that is functionally equivalent), including components which are not structurally equivalent to the disclosed structure which performs the function in the illustrated exemplary embodiments of the disclosure.


Specific examples of systems, methods and apparatus have been described herein for purposes of illustration. These are only examples. The technology provided herein can be applied to systems other than the example systems described above. Many alterations, modifications, additions, omissions, and permutations are possible within the practice of this disclosure. This disclosure includes variations on described embodiments that would be apparent to the skilled addressee, including variations obtained by: replacing features, elements and/or acts with equivalent features, elements and/or acts; mixing and matching of features, elements and/or acts from different embodiments; combining features, elements and/or acts from embodiments as described herein with features, elements and/or acts of other technology; and/or omitting combining features, elements and/or acts from described embodiments.


While processes or blocks are presented in a given order, alternative examples may perform routines having steps, or employ systems having blocks, in a different order, and some processes or blocks may be deleted, moved, added, subdivided, combined, and/or modified to provide alternative or subcombinations. Each of these processes or blocks may be implemented in a variety of different ways. Also, while processes or blocks are at times shown as being performed in series, these processes or blocks may instead be performed in parallel, or may be performed at different times.


Various features are described herein as being present in “some embodiments”. Such features are not mandatory and may not be present in all embodiments. Embodiments of the disclosure may include zero, any one or any combination of two or more of such features. This is limited only to the extent that certain ones of such features may be incompatible with other ones of such features in the sense that it would be impossible for a person of ordinary skill in the art to construct a practical embodiment that combines such incompatible features. Consequently, separate or combined statements in the description that “some embodiments” possess feature A and “some embodiments” possess feature B should be interpreted as an express indication that the disclosure also contemplate embodiments which combine features A and B (unless the description states otherwise or features A and B are fundamentally incompatible).


It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions, omissions, and sub-combinations as may reasonably be inferred. The scope of the claims should not be limited by the embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.

Claims
  • 1. An apparatus for controlling blood pressure in a subject, the apparatus comprising: an input for receiving a BP signal indicative of a blood pressure measurement;a feedback control circuit connected to a sensor to receive the BP signal from the input and to deliver a stimulation control signal to an output, the feedback control circuit configured to: compare the blood pressure measurement to a target blood pressure range, whereinif the comparison indicates that the blood pressure measurement is below the target blood pressure range increase a level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range; andif the comparison indicates that the blood pressure measurement is above the target blood pressure range decrease a level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range;wherein the apparatus comprises a processor configured to receive a measurement of bladder function and to control blood pressure and at least one of bladder and bowel function by respectively applying a blood pressure stimulation signal and a bladder/bowel stimulation signal;wherein the blood pressure stimulation signal and bladder/bowel stimulation signal are different from one another;wherein the blood pressure stimulation signal and bladder/bowel stimulation signal are electrical signals and the blood pressure stimulation signal and bladder/bowel stimulation signal are delivered using different sets of electrodes of an electrode array implanted adjacent to a subject's spinal cord; andwherein the measurement of bladder function is a measure of bladder volume.
  • 2. The apparatus according to claim 1, wherein the feedback control circuit stores an increment value and a lag time and is configured to increase the level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range by repeatedly increasing the level of the stimulation control signal by the increment value, waiting for the lag time, obtaining a new blood pressure measurement from the input and comparing the new blood pressure measurement to the target blood pressure range.
  • 3. The apparatus according to claim 2, wherein the lag time is between a few seconds to 15 minutes.
  • 4. The apparatus according to claim 1, wherein the stimulation control signal is continuously applied and the level of the stimulation control signal is adjusted based on the blood pressure measurement.
  • 5. The apparatus according to claim 1, further comprising an electrical pulse generator connected to receive the stimulation control signal and to generate electrical pulses and apply the generated electrical pulses to an electrode array, wherein increasing the level of the stimulation control signal causes the electrical pulse generator to increase a voltage and/or a current and/or a frequency and/or a pulse width of generated electrical pulses.
  • 6. The apparatus according to claim 5, wherein the electrode array comprises a transdermal electrode array and the stimulation control signal controls for a stimulation output comprising a voltage between about 0.1 V to about 100 V and an amperage between about 0 mA to about 100 mA.
  • 7. The apparatus according to claim 5, wherein the electrode array comprises an epidural electrode array and the stimulation control signal controls for a stimulation output comprising a voltage between about 0.1 V to about 20 V and an amperage between about 0 mA to about 100 mA.
  • 8. The apparatus according to claim 5, wherein the stimulation control signal controls for a stimulation output comprising electrical pulses presented at a pulse frequency between about 5 Hz to 10 kHz.
  • 9. The apparatus according to claim 5, wherein the stimulation control signal controls for a stimulation output comprising electrical pulses having a pulse width between about 0.002 seconds to about 20 seconds.
  • 10. The apparatus according to claim 9, wherein the pulse width is between about 0.033 seconds to about 0.17 seconds.
  • 11. The apparatus according to claim 5, wherein the electrode array is a transdermal electrode array or an epidural electrode array.
  • 12. The apparatus according to claim 1, further comprising a user control, wherein activation of the user control triggers the apparatus to deliver the bladder/bowel stimulation signal.
  • 13. The apparatus according to claim 12, wherein the apparatus is configured to interrupt or inhibit delivery of the blood pressure stimulation signal while delivering the bladder/bowel stimulation signal.
  • 14. The apparatus according to claim 1, wherein the blood pressure measurement is a systolic measurement.
  • 15. A method for operating an apparatus to control a subject's blood pressure, the method comprising: receiving at the apparatus a signal containing a blood pressure measurement indicative of the subject's blood pressure;comparing the blood pressure measurement to a predetermined target range stored in a data store accessible to the apparatus; wherein if the comparison indicates that the blood pressure measurement is below the target blood pressure range increasing a level of a stimulation control signal until the blood pressure measurement is in the target blood pressure range; andif the comparison indicates that the blood pressure measurement is above the target blood pressure range decreasing the level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range;wherein the apparatus is connected to receive a measurement of bladder function and is configured to control blood pressure and one or both of bladder and bowel function by respectively applying a blood pressure stimulation signal and a bladder/bowel stimulation signal;wherein the blood pressure stimulation signal and bladder/bowel stimulation signal are different from one another;wherein the blood pressure stimulation signal and bladder/bowel stimulation signal are electrical signals and the blood pressure stimulation signal and bladder/bowel stimulation signal are delivered using different sets of electrodes of an electrode array implanted adjacent to a subject's spinal cord; andwherein the measurement of bladder function is a measure of bladder volume.
  • 16. The method according to claim 15, wherein when the comparison indicates that the blood pressure measurement is below the target blood pressure range, increasing the level of the stimulation control signal until the blood pressure measurement is in the target blood pressure range by repeatedly increasing the level of the stimulation control signal by an increment value, waiting for a lag time, obtaining a new blood pressure measurement and comparing the new blood pressure measurement to the target blood pressure range.
  • 17. The method according to claim 16, wherein the lag time is between a few seconds to 15 minutes.
  • 18. The method according to claim 15, wherein the stimulation control signal controls a continuous stimulation and the level of the stimulation control signal is iteratively adjusted based on the blood pressure measurement.
  • 19. The method according to claim 15, wherein the stimulation control signal is connected to control an electrical pulse generator to generate electrical pulses, wherein increasing the level of the stimulation control signal causes the electrical pulse generator to increase a voltage and/or a current and/or a frequency and/or a pulse width of the generated electrical pulses.
  • 20. The method according to claim 15, wherein the blood pressure measurement is a systolic measurement.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. Non-Provisional patent application Ser. No. 16/486,788, entitled “APPARATUS AND METHODS FOR MAINTAINING PHYSIOLOGICAL FUNCTIONS”, and filed on Aug. 16, 2019. U.S. Non-Provisional patent application Ser. No. 16/486,788 is a U.S. National Phase of International Application No. PCT/CA2018/050184 entitled “APPARATUS AND METHODS FOR MAINTAINING PHYSIOLOGICAL FUNCTIONS”, filed Feb. 16, 2018. International Application No. PCT/CA2018/050184 claims benefit of U.S. Provisional Application No. 62/460,224 filed Feb. 17, 2017 and entitled SERVO-CONTROLLED DEVICE TO MAINTAIN PHYSIOLOGICAL FUNCTIONING, U.S. Provisional Application No. 62/470,468 filed Mar. 13, 2017 and entitled SERVO CONTROLLED INTERFACE TO CONTROL ELECTRICAL STIMULATION FOR RESTORING PHYSIOLOGICAL FUNCTIONING, and U.S. Provisional Application No. 62/581,305 filed Nov. 3, 2017 and entitled SERVO CONTROLLED INTERFACE TO CONTROL ELECTRICAL STIMULATION FOR RESTORING PHYSIOLOGICAL FUNCTIONING. The entire contents of each of the above-listed applications are hereby incorporated by reference for all purposes.

US Referenced Citations (616)
Number Name Date Kind
2868343 Sproul Jan 1959 A
3543761 Bradley Dec 1970 A
3650277 Sjostrand et al. Mar 1972 A
3662758 Glover May 1972 A
3724467 Avery et al. Apr 1973 A
4044774 Corbin et al. Aug 1977 A
4102344 Conway et al. Jul 1978 A
4141365 Fischell et al. Feb 1979 A
4285347 Hess Aug 1981 A
4340063 Maurer Jul 1982 A
4379462 Borkan et al. Apr 1983 A
4398537 Holmbo Aug 1983 A
4414986 Dickhudt et al. Nov 1983 A
4538624 Tarjan Sep 1985 A
4549556 Tarjan et al. Oct 1985 A
4559948 Liss et al. Dec 1985 A
4569352 Petrofsky et al. Feb 1986 A
4573481 Bullara Mar 1986 A
4724842 Charters Feb 1988 A
4800898 Hess et al. Jan 1989 A
4934368 Lynch Jun 1990 A
4969452 Petrofsky et al. Nov 1990 A
5002053 Garcia-Rill et al. Mar 1991 A
5031618 Mullett Jul 1991 A
5066272 Eaton et al. Nov 1991 A
5081989 Graupe et al. Jan 1992 A
5121754 Mullett Jun 1992 A
5344439 Otten Sep 1994 A
5354320 Schaldach et al. Oct 1994 A
5366813 Berlin Nov 1994 A
5374285 Vaiani et al. Dec 1994 A
5417719 Hull et al. May 1995 A
5476441 Durfee et al. Dec 1995 A
5562718 Palermo Oct 1996 A
5643330 Holsheimer et al. Jul 1997 A
5733322 Starkebaum Mar 1998 A
5983141 Sluijter et al. Nov 1999 A
6058331 King May 2000 A
6066163 John May 2000 A
6104957 Alo et al. Aug 2000 A
6122548 Starkebaum et al. Sep 2000 A
6308103 Gielen Oct 2001 B1
6319241 King et al. Nov 2001 B1
6463327 Lurie et al. Oct 2002 B1
6470213 Alley Oct 2002 B1
6500110 Davey et al. Dec 2002 B1
6503231 Prausnitz et al. Jan 2003 B1
6505074 Boveja et al. Jan 2003 B2
6516227 Meadows et al. Feb 2003 B1
6551849 Kenney Apr 2003 B1
6587724 Mann Jul 2003 B2
6662053 Borkan Dec 2003 B2
6666831 Edgerton et al. Dec 2003 B1
6685729 Gonzalez Feb 2004 B2
6748276 Daignault, Jr. et al. Jun 2004 B1
6819956 DiLorenzo Nov 2004 B2
6839594 Cohen et al. Jan 2005 B2
6862479 Whitehurst et al. Mar 2005 B1
6871099 Whitehurst et al. Mar 2005 B1
6878112 Linberg et al. Apr 2005 B2
6892098 Ayal et al. May 2005 B2
6895280 Meadows et al. May 2005 B2
6895283 Erickson et al. May 2005 B2
6937891 Leinders et al. Aug 2005 B2
6950706 Rodriguez et al. Sep 2005 B2
6975907 Zanakis et al. Dec 2005 B2
6988006 King et al. Jan 2006 B2
6999820 Jordan Feb 2006 B2
7020521 Brewer et al. Mar 2006 B1
7024247 Gliner et al. Apr 2006 B2
7035690 Goetz Apr 2006 B2
7047084 Erickson et al. May 2006 B2
7065408 Herman et al. Jun 2006 B2
7096070 Jenkins et al. Aug 2006 B1
7110820 Tcheng et al. Sep 2006 B2
7127287 Duncan et al. Oct 2006 B2
7127296 Bradley Oct 2006 B2
7127297 Law et al. Oct 2006 B2
7149773 Haller et al. Dec 2006 B2
7153242 Goffer Dec 2006 B2
7184837 Goetz Feb 2007 B2
7200443 Faul Apr 2007 B2
7209787 DiLorenzo Apr 2007 B2
7228179 Campen et al. Jun 2007 B2
7239920 Thacker et al. Jul 2007 B1
7251529 Greenwood-Van Meerveld Jul 2007 B2
7252090 Goetz Aug 2007 B2
7313440 Miesel Dec 2007 B2
7324853 Ayal et al. Jan 2008 B2
7330760 Heruth et al. Feb 2008 B2
7337005 Kim et al. Feb 2008 B2
7337006 Kim et al. Feb 2008 B2
7340298 Barbut Mar 2008 B1
7381192 Brodard et al. Jun 2008 B2
7415309 McIntyre Aug 2008 B2
7463927 Chaouat Dec 2008 B1
7463928 Lee et al. Dec 2008 B2
7467016 Colborn Dec 2008 B2
7493170 Segel et al. Feb 2009 B1
7496404 Meadows et al. Feb 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7536226 Williams et al. May 2009 B2
7544185 Bengtsson Jun 2009 B2
7584000 Erickson Sep 2009 B2
7590454 Garabedian et al. Sep 2009 B2
7603178 North et al. Oct 2009 B2
7620502 Selifonov et al. Nov 2009 B2
7628750 Cohen et al. Dec 2009 B2
7647115 Levin et al. Jan 2010 B2
7660636 Castel et al. Feb 2010 B2
7697995 Cross, Jr. et al. Apr 2010 B2
7725193 Chu May 2010 B1
7729781 Swoyer et al. Jun 2010 B2
7734340 De Ridder Jun 2010 B2
7734351 Testerman et al. Jun 2010 B2
7742037 Sako et al. Jun 2010 B2
7769463 Katsnelson Aug 2010 B2
7797057 Harris Sep 2010 B2
7801601 Maschino et al. Sep 2010 B2
7813803 Heruth et al. Oct 2010 B2
7813809 Strother et al. Oct 2010 B2
7856264 Firlik et al. Dec 2010 B2
7877146 Rezai et al. Jan 2011 B2
7890182 Parramon et al. Feb 2011 B2
7949395 Kuzma May 2011 B2
7949403 Palermo et al. May 2011 B2
7987000 Moffitt et al. Jul 2011 B2
7991465 Bartic et al. Aug 2011 B2
8019427 Moffitt Sep 2011 B2
8050773 Zhu Nov 2011 B2
8108051 Cross, Jr. et al. Jan 2012 B2
8108052 Boling Jan 2012 B2
8131358 Moffitt et al. Mar 2012 B2
8135473 Miesel et al. Mar 2012 B2
8155750 Jaax et al. Apr 2012 B2
8168481 Hanaoka et al. May 2012 B2
8170660 Dacey, Jr. et al. May 2012 B2
8190262 Gerber et al. May 2012 B2
8195304 Strother et al. Jun 2012 B2
8214048 Whitehurst et al. Jul 2012 B1
8229565 Kim et al. Jul 2012 B2
8239038 Wolf, II Aug 2012 B2
8260436 Gerber et al. Sep 2012 B2
8271099 Swanson et al. Sep 2012 B1
8295936 Wahlstrand et al. Oct 2012 B2
8311644 Moffitt et al. Nov 2012 B2
8326569 Lee et al. Dec 2012 B2
8332029 Glukhovsky et al. Dec 2012 B2
8332047 Libbus et al. Dec 2012 B2
8346366 Arle et al. Jan 2013 B2
8352036 DiMarco et al. Jan 2013 B2
8355791 Moffitt Jan 2013 B2
8355797 Caparso et al. Jan 2013 B2
8364273 De Ridder Jan 2013 B2
8369961 Christman et al. Feb 2013 B2
8374696 Sanchez et al. Feb 2013 B2
8412345 Moffitt Apr 2013 B2
8428728 Sachs Apr 2013 B2
8442655 Moffitt et al. May 2013 B2
8452406 Arcot-Krishnamurthy et al. May 2013 B2
8543200 Lane et al. Sep 2013 B2
8588884 Hegde et al. Nov 2013 B2
8626300 Demarais et al. Jan 2014 B2
8700145 Kilgard et al. Apr 2014 B2
8712546 Kim et al. Apr 2014 B2
8740825 Ehrenreich et al. Jun 2014 B2
8750957 Tang et al. Jun 2014 B2
8768481 Lane Jul 2014 B2
8805542 Tai et al. Aug 2014 B2
9072891 Rao Jul 2015 B1
9079039 Carlson et al. Jul 2015 B2
9101769 Edgerton et al. Aug 2015 B2
9205259 Kim et al. Dec 2015 B2
9205260 Kim et al. Dec 2015 B2
9205261 Kim et al. Dec 2015 B2
9248291 Mashiach Feb 2016 B2
9272139 Hamilton et al. Mar 2016 B2
9272143 Libbus et al. Mar 2016 B2
9283391 Ahmed Mar 2016 B2
9314630 Levin et al. Apr 2016 B2
9393409 Edgerton et al. Jul 2016 B2
9409023 Burdick et al. Aug 2016 B2
9415218 Edgerton et al. Aug 2016 B2
9421365 Sumners et al. Aug 2016 B2
9597517 Moffitt Mar 2017 B2
9610442 Yoo et al. Apr 2017 B2
9802052 Marnfeldt Oct 2017 B2
9895545 Rao et al. Feb 2018 B2
9993642 Gerasimenko et al. Jun 2018 B2
10092750 Edgerton et al. Oct 2018 B2
10124166 Edgerton et al. Nov 2018 B2
10137299 Lu et al. Nov 2018 B2
10449371 Serrano Carmona Oct 2019 B2
10751533 Edgerton et al. Aug 2020 B2
10773074 Liu et al. Sep 2020 B2
10806927 Edgerton et al. Oct 2020 B2
10806935 Rao et al. Oct 2020 B2
11097122 Lu Aug 2021 B2
11123312 Lu et al. Sep 2021 B2
20010016266 Okazaki et al. Aug 2001 A1
20010032992 Wendt Oct 2001 A1
20020042814 Fukasawa et al. Apr 2002 A1
20020052539 Haller et al. May 2002 A1
20020055779 Andrews May 2002 A1
20020083240 Hoese et al. Jun 2002 A1
20020111661 Cross et al. Aug 2002 A1
20020115945 Herman et al. Aug 2002 A1
20020188332 Lurie et al. Dec 2002 A1
20020193843 Hill et al. Dec 2002 A1
20030032992 Thacker et al. Feb 2003 A1
20030078633 Firlik et al. Apr 2003 A1
20030093021 Goffer May 2003 A1
20030100933 Ayal et al. May 2003 A1
20030114894 Dar et al. Jun 2003 A1
20030158583 Burnett et al. Aug 2003 A1
20030220679 Han Nov 2003 A1
20030233137 Paul, Jr. Dec 2003 A1
20040039425 Greenwood-Van Meerveld Feb 2004 A1
20040044380 Bruninga et al. Mar 2004 A1
20040111118 Hill et al. Jun 2004 A1
20040111126 Tanagho et al. Jun 2004 A1
20040122483 Nathan et al. Jun 2004 A1
20040127954 McDonald, III Jul 2004 A1
20040133248 Frei et al. Jul 2004 A1
20040138518 Rise et al. Jul 2004 A1
20040172027 Speitling et al. Sep 2004 A1
20040172097 Brodard et al. Sep 2004 A1
20040181263 Balzer et al. Sep 2004 A1
20040267320 Taylor et al. Dec 2004 A1
20050004622 Cullen et al. Jan 2005 A1
20050061315 Lee et al. Mar 2005 A1
20050070982 Heruth et al. Mar 2005 A1
20050075669 King Apr 2005 A1
20050075678 Faul Apr 2005 A1
20050090756 Wolf et al. Apr 2005 A1
20050101827 Delisle May 2005 A1
20050102007 Ayal et al. May 2005 A1
20050113882 Cameron et al. May 2005 A1
20050119713 Whitehurst et al. Jun 2005 A1
20050125045 Brighton et al. Jun 2005 A1
20050209655 Bradley et al. Sep 2005 A1
20050231186 Saavedra Barrera et al. Oct 2005 A1
20050246004 Cameron et al. Nov 2005 A1
20050277999 Strother et al. Dec 2005 A1
20050278000 Strother et al. Dec 2005 A1
20060003090 Rodger et al. Jan 2006 A1
20060015153 Gliner et al. Jan 2006 A1
20060018360 Tai et al. Jan 2006 A1
20060041225 Wallace et al. Feb 2006 A1
20060041295 Osypka Feb 2006 A1
20060089696 Olsen et al. Apr 2006 A1
20060100671 Ridder May 2006 A1
20060111754 Rezai et al. May 2006 A1
20060122678 Olsen et al. Jun 2006 A1
20060142337 Ikeura et al. Jun 2006 A1
20060142816 Fruitman et al. Jun 2006 A1
20060142822 Tulgar Jun 2006 A1
20060149333 Tanagho et al. Jul 2006 A1
20060149337 John Jul 2006 A1
20060189839 Laniado et al. Aug 2006 A1
20060195153 DiUbaldi et al. Aug 2006 A1
20060239482 Hatoum Oct 2006 A1
20060241356 Flaherty Oct 2006 A1
20060282127 Zealear Dec 2006 A1
20070004567 Shetty et al. Jan 2007 A1
20070016097 Farquhar et al. Jan 2007 A1
20070016266 Paul, Jr. Jan 2007 A1
20070016329 Herr et al. Jan 2007 A1
20070021513 Agee et al. Jan 2007 A1
20070027395 Gerber Feb 2007 A1
20070047852 Sharp et al. Mar 2007 A1
20070049814 Muccio Mar 2007 A1
20070055337 Tanrisever Mar 2007 A1
20070060954 Cameron et al. Mar 2007 A1
20070060980 Strother et al. Mar 2007 A1
20070067003 Sanchez et al. Mar 2007 A1
20070073357 Rooney et al. Mar 2007 A1
20070083240 Peterson et al. Apr 2007 A1
20070100389 Jaax et al. May 2007 A1
20070121702 LaGuardia et al. May 2007 A1
20070121709 Ittogi May 2007 A1
20070142874 John Jun 2007 A1
20070150023 Ignagni et al. Jun 2007 A1
20070156172 Alvarado Jul 2007 A1
20070156179 S. E. Jul 2007 A1
20070156200 Kornet et al. Jul 2007 A1
20070168008 Olsen Jul 2007 A1
20070179534 Firlik et al. Aug 2007 A1
20070179579 Feler et al. Aug 2007 A1
20070191709 Swanson Aug 2007 A1
20070208381 Hill et al. Sep 2007 A1
20070233204 Lima et al. Oct 2007 A1
20070255372 Metzler et al. Nov 2007 A1
20070265621 Matthis et al. Nov 2007 A1
20070265679 Bradley et al. Nov 2007 A1
20070265691 Swanson Nov 2007 A1
20070276449 Gunter et al. Nov 2007 A1
20070276450 Meadows et al. Nov 2007 A1
20070293910 Strother et al. Dec 2007 A1
20080002227 Tsujimoto Jan 2008 A1
20080004674 King et al. Jan 2008 A1
20080009927 Vilims Jan 2008 A1
20080021513 Thacker et al. Jan 2008 A1
20080027346 Litt et al. Jan 2008 A1
20080046049 Skubitz et al. Feb 2008 A1
20080051851 Lin Feb 2008 A1
20080071325 Bradley Mar 2008 A1
20080077192 Harry et al. Mar 2008 A1
20080103579 Gerber May 2008 A1
20080105185 Kuhlman May 2008 A1
20080140152 Imran et al. Jun 2008 A1
20080140162 Goetz et al. Jun 2008 A1
20080140169 Imran Jun 2008 A1
20080147143 Popovic et al. Jun 2008 A1
20080154329 Pyles et al. Jun 2008 A1
20080183224 Barolat Jul 2008 A1
20080200749 Zheng et al. Aug 2008 A1
20080202940 Jiang et al. Aug 2008 A1
20080207985 Farone Aug 2008 A1
20080208287 Palermo et al. Aug 2008 A1
20080215113 Pawlowicz Sep 2008 A1
20080221653 Agrawal et al. Sep 2008 A1
20080224226 Suzuki et al. Sep 2008 A1
20080228241 Sachs Sep 2008 A1
20080228250 Mironer Sep 2008 A1
20080234121 Kim et al. Sep 2008 A1
20080234791 Arle et al. Sep 2008 A1
20080279896 Heinen et al. Nov 2008 A1
20080294211 Moffitt Nov 2008 A1
20080294226 Moffitt et al. Nov 2008 A1
20090012436 Lanfermann et al. Jan 2009 A1
20090024997 Kobayashi Jan 2009 A1
20090093854 Leung et al. Apr 2009 A1
20090112281 Miyazawa et al. Apr 2009 A1
20090118365 Benson, III et al. May 2009 A1
20090131995 Sloan et al. May 2009 A1
20090157141 Chiao et al. Jun 2009 A1
20090198305 Naroditsky et al. Aug 2009 A1
20090204173 Fang et al. Aug 2009 A1
20090229166 Sawrie Sep 2009 A1
20090270960 Zhao et al. Oct 2009 A1
20090281529 Carriazo Nov 2009 A1
20090281599 Thacker et al. Nov 2009 A1
20090293270 Brindley et al. Dec 2009 A1
20090299166 Nishida et al. Dec 2009 A1
20090299167 Seymour Dec 2009 A1
20090306491 Haggers Dec 2009 A1
20100004715 Fahey Jan 2010 A1
20100010646 Drew et al. Jan 2010 A1
20100023103 Elborno Jan 2010 A1
20100029040 Nomoto Feb 2010 A1
20100042193 Slavin Feb 2010 A1
20100070007 Parker et al. Mar 2010 A1
20100114205 Donofrio et al. May 2010 A1
20100114239 McDonald, III May 2010 A1
20100125313 Lee et al. May 2010 A1
20100137238 Gan et al. Jun 2010 A1
20100137938 Kishawi et al. Jun 2010 A1
20100145428 Cameron et al. Jun 2010 A1
20100152811 Flaherty Jun 2010 A1
20100166546 Mahan et al. Jul 2010 A1
20100168820 Maniak et al. Jul 2010 A1
20100185253 Dimarco et al. Jul 2010 A1
20100198298 Glukhovsky et al. Aug 2010 A1
20100217355 Tass et al. Aug 2010 A1
20100228310 Shuros et al. Sep 2010 A1
20100241121 Logan et al. Sep 2010 A1
20100241191 Testerman et al. Sep 2010 A1
20100268299 Farone Oct 2010 A1
20100274312 Alataris et al. Oct 2010 A1
20100280570 Sturm et al. Nov 2010 A1
20100305660 Hegi et al. Dec 2010 A1
20100312304 York et al. Dec 2010 A1
20100318168 Bighetti Dec 2010 A1
20100331925 Peterson Dec 2010 A1
20110006793 Peschke et al. Jan 2011 A1
20110009919 Carbunaru et al. Jan 2011 A1
20110016081 Basak et al. Jan 2011 A1
20110029040 Walker et al. Feb 2011 A1
20110029044 Hyde et al. Feb 2011 A1
20110034277 Brandes Feb 2011 A1
20110034977 Janik et al. Feb 2011 A1
20110040349 Graupe Feb 2011 A1
20110054567 Lane et al. Mar 2011 A1
20110054568 Lane et al. Mar 2011 A1
20110054570 Lane Mar 2011 A1
20110054579 Kumar et al. Mar 2011 A1
20110077660 Janik et al. Mar 2011 A1
20110082515 Libbus et al. Apr 2011 A1
20110084489 Kaplan Apr 2011 A1
20110093043 Torgerson et al. Apr 2011 A1
20110112601 Meadows et al. May 2011 A1
20110125203 Simon et al. May 2011 A1
20110130804 Lin et al. Jun 2011 A1
20110152967 Simon et al. Jun 2011 A1
20110160810 Griffith Jun 2011 A1
20110166546 Jaax et al. Jul 2011 A1
20110184482 Eberman et al. Jul 2011 A1
20110184488 De Ridder Jul 2011 A1
20110184489 Nicolelis et al. Jul 2011 A1
20110202107 Sunagawa et al. Aug 2011 A1
20110208265 Erickson et al. Aug 2011 A1
20110213266 Williams et al. Sep 2011 A1
20110218590 Degiorgio et al. Sep 2011 A1
20110218594 Doron et al. Sep 2011 A1
20110224153 Levitt et al. Sep 2011 A1
20110224665 Crosby et al. Sep 2011 A1
20110224752 Rolston et al. Sep 2011 A1
20110224753 Palermo et al. Sep 2011 A1
20110224757 Zdeblick et al. Sep 2011 A1
20110230101 Tang et al. Sep 2011 A1
20110230701 Simon et al. Sep 2011 A1
20110230702 Honour Sep 2011 A1
20110231326 Marino Sep 2011 A1
20110237221 Prakash et al. Sep 2011 A1
20110237921 Prakash et al. Sep 2011 A1
20110245734 Wagner et al. Oct 2011 A1
20110276107 Simon et al. Nov 2011 A1
20110288609 Tehrani et al. Nov 2011 A1
20110295100 Hegde et al. Dec 2011 A1
20120006793 Swanson Jan 2012 A1
20120011950 Kracke Jan 2012 A1
20120013041 Cao et al. Jan 2012 A1
20120013126 Molloy Jan 2012 A1
20120016448 Lee Jan 2012 A1
20120029528 MacDonald et al. Feb 2012 A1
20120035684 Thompson et al. Feb 2012 A1
20120041518 Kim et al. Feb 2012 A1
20120052432 Matsuura Mar 2012 A1
20120059432 Emborg et al. Mar 2012 A1
20120071250 O'Neil et al. Mar 2012 A1
20120071950 Archer Mar 2012 A1
20120083709 Parker et al. Apr 2012 A1
20120101326 Simon et al. Apr 2012 A1
20120109251 Lebedev et al. May 2012 A1
20120109295 Fan May 2012 A1
20120116476 Kothandaraman May 2012 A1
20120123223 Freeman et al. May 2012 A1
20120123293 Shah et al. May 2012 A1
20120126392 Kälvesten et al. May 2012 A1
20120136408 Grill et al. May 2012 A1
20120165899 Gliner Jun 2012 A1
20120172222 Artigas Puerto Jul 2012 A1
20120172246 Nguyen et al. Jul 2012 A1
20120172946 Alataris et al. Jul 2012 A1
20120179222 Jaax et al. Jul 2012 A1
20120185020 Simon et al. Jul 2012 A1
20120197338 Su et al. Aug 2012 A1
20120203055 Pletnev Aug 2012 A1
20120203131 DiLorenzo Aug 2012 A1
20120221073 Southwell et al. Aug 2012 A1
20120232615 Barolat et al. Sep 2012 A1
20120252380 Kawakita Oct 2012 A1
20120252874 Feinstein et al. Oct 2012 A1
20120259380 Pyles Oct 2012 A1
20120271372 Osorio Oct 2012 A1
20120277824 Li Nov 2012 A1
20120277834 Mercanzini et al. Nov 2012 A1
20120283697 Kim et al. Nov 2012 A1
20120302821 Burnett Nov 2012 A1
20120310305 Kaula et al. Dec 2012 A1
20120310315 Savage et al. Dec 2012 A1
20120330321 Johnson et al. Dec 2012 A1
20120330391 Bradley et al. Dec 2012 A1
20130012853 Brown Jan 2013 A1
20130013041 Glukhovsky et al. Jan 2013 A1
20130026640 Ito et al. Jan 2013 A1
20130030312 Keel et al. Jan 2013 A1
20130030319 Hettrick et al. Jan 2013 A1
20130030501 Feler et al. Jan 2013 A1
20130035745 Ahmed et al. Feb 2013 A1
20130053734 Barriskill et al. Feb 2013 A1
20130053922 Ahmed et al. Feb 2013 A1
20130066392 Simon et al. Mar 2013 A1
20130085317 Feinstein Apr 2013 A1
20130085361 Mercanzini et al. Apr 2013 A1
20130096640 Possover Apr 2013 A1
20130096661 Greenberg et al. Apr 2013 A1
20130096662 Swanson Apr 2013 A1
20130110196 Alataris et al. May 2013 A1
20130116751 Moffitt et al. May 2013 A1
20130123568 Hamilton et al. May 2013 A1
20130123659 Bartol et al. May 2013 A1
20130138167 Bradley et al. May 2013 A1
20130165991 Kim et al. Jun 2013 A1
20130197408 Goldfarb et al. Aug 2013 A1
20130204324 Thacker et al. Aug 2013 A1
20130211477 Cullen et al. Aug 2013 A1
20130237948 Donders et al. Sep 2013 A1
20130253222 Nakao Sep 2013 A1
20130253229 Sawant et al. Sep 2013 A1
20130253299 Weber et al. Sep 2013 A1
20130253611 Lee et al. Sep 2013 A1
20130268016 Xi et al. Oct 2013 A1
20130268021 Moffitt Oct 2013 A1
20130281890 Mishelevich Oct 2013 A1
20130289446 Stone et al. Oct 2013 A1
20130289650 Karlsson et al. Oct 2013 A1
20130289664 Johanek Oct 2013 A1
20130289667 Wacnik et al. Oct 2013 A1
20130296965 Mokelke et al. Nov 2013 A1
20130303873 Vörös et al. Nov 2013 A1
20130304159 Simon et al. Nov 2013 A1
20130310211 Wilton et al. Nov 2013 A1
20130310911 Tai et al. Nov 2013 A1
20140005753 Carbunaru Jan 2014 A1
20140031893 Walker et al. Jan 2014 A1
20140046407 Ben-Ezra et al. Feb 2014 A1
20140058292 Alford et al. Feb 2014 A1
20140058490 DiMarco Feb 2014 A1
20140066950 MacDonald et al. Mar 2014 A1
20140067007 Drees et al. Mar 2014 A1
20140067354 Kaula et al. Mar 2014 A1
20140074190 Griffith Mar 2014 A1
20140081011 Vaught Mar 2014 A1
20140081071 Simon et al. Mar 2014 A1
20140088674 Bradley Mar 2014 A1
20140100633 Mann et al. Apr 2014 A1
20140107397 Simon et al. Apr 2014 A1
20140107398 Simon et al. Apr 2014 A1
20140114374 Rooney et al. Apr 2014 A1
20140163640 Edgerton et al. Jun 2014 A1
20140172045 Yip et al. Jun 2014 A1
20140180361 Burdick et al. Jun 2014 A1
20140213842 Simon et al. Jul 2014 A1
20140228905 Bolea Aug 2014 A1
20140236257 Parker et al. Aug 2014 A1
20140243923 Doan et al. Aug 2014 A1
20140277271 Chan et al. Sep 2014 A1
20140296752 Edgerton et al. Oct 2014 A1
20140303901 Sadeh Oct 2014 A1
20140316484 Edgerton et al. Oct 2014 A1
20140316503 Tai et al. Oct 2014 A1
20140324118 Simon et al. Oct 2014 A1
20140330067 Jordan Nov 2014 A1
20140330335 Errico et al. Nov 2014 A1
20140336722 Rocon De Lima et al. Nov 2014 A1
20140357936 Simon et al. Dec 2014 A1
20150005840 Pal et al. Jan 2015 A1
20150065559 Feinstein et al. Mar 2015 A1
20150066111 Blum et al. Mar 2015 A1
20150165226 Simon et al. Jun 2015 A1
20150182784 Barriskill et al. Jul 2015 A1
20150190634 Rezai et al. Jul 2015 A1
20150196231 Ziaie et al. Jul 2015 A1
20150217120 Nandra et al. Aug 2015 A1
20150231396 Burdick et al. Aug 2015 A1
20150265830 Simon et al. Sep 2015 A1
20150328462 Griffith Nov 2015 A1
20160001096 Mishelevich Jan 2016 A1
20160030737 Gerasimenko et al. Feb 2016 A1
20160030748 Edgerton et al. Feb 2016 A1
20160030750 Bokil et al. Feb 2016 A1
20160045727 Rezai et al. Feb 2016 A1
20160045731 Simon et al. Feb 2016 A1
20160074663 De Ridder Mar 2016 A1
20160121109 Edgerton et al. May 2016 A1
20160121114 Simon et al. May 2016 A1
20160121116 Simon et al. May 2016 A1
20160121121 Mashiach May 2016 A1
20160143588 Hoitink et al. May 2016 A1
20160157389 Hwang Jun 2016 A1
20160220813 Edgerton et al. Aug 2016 A1
20160235977 Lu et al. Aug 2016 A1
20160175586 Edgerton et al. Sep 2016 A1
20160271413 Vallejo et al. Sep 2016 A1
20160279418 Courtine et al. Sep 2016 A1
20160279429 Hershey et al. Sep 2016 A1
20160310739 Burdick et al. Oct 2016 A1
20170007320 Levin et al. Jan 2017 A1
20170056661 Lin et al. Mar 2017 A1
20170128729 Netoff et al. May 2017 A1
20170007831 Edgerton et al. Jun 2017 A1
20170157389 Tai et al. Jun 2017 A1
20170157396 Dixon et al. Jun 2017 A1
20170161454 Grill et al. Jun 2017 A1
20170165497 Lu Jun 2017 A1
20170173326 Bloch et al. Jun 2017 A1
20170246450 Liu et al. Aug 2017 A1
20170246452 Liu et al. Aug 2017 A1
20170266455 Steinke Sep 2017 A1
20170274209 Edgerton et al. Sep 2017 A1
20170296837 Jin Oct 2017 A1
20170354819 Bloch et al. Dec 2017 A1
20170361093 Yoo et al. Dec 2017 A1
20180056078 Kashyap et al. Mar 2018 A1
20180085583 Zhang et al. Mar 2018 A1
20180104479 Grill et al. Apr 2018 A1
20180110992 Parramon et al. Apr 2018 A1
20180125416 Schwarz et al. May 2018 A1
20180178008 Bouton et al. Jun 2018 A1
20180185642 Lu Jul 2018 A1
20180185648 Nandra et al. Jul 2018 A1
20180193655 Zhang et al. Jul 2018 A1
20180229037 Edgerton et al. Aug 2018 A1
20180229038 Burdick et al. Aug 2018 A1
20180236240 Harkema et al. Aug 2018 A1
20180256906 Pivonka et al. Sep 2018 A1
20180280693 Edgerton et al. Oct 2018 A1
20180353755 Edgerton et al. Dec 2018 A1
20180361146 Gerasimenko et al. Dec 2018 A1
20190022371 Chang et al. Jan 2019 A1
20190033622 Olgun et al. Jan 2019 A1
20190160294 Peterson et al. May 2019 A1
20190167987 Lu et al. Jun 2019 A1
20190192864 Koop et al. Jun 2019 A1
20190247650 Tran Aug 2019 A1
20190269917 Courtine et al. Sep 2019 A1
20190381313 Lu Dec 2019 A1
20190381328 Wechter et al. Dec 2019 A1
20200155865 Lu May 2020 A1
20200228901 Baek Jul 2020 A1
20210069052 Burke Mar 2021 A1
20210187278 Lu Jun 2021 A1
20210236837 Lu Aug 2021 A1
20210378991 Lu et al. Dec 2021 A1
Foreign Referenced Citations (141)
Number Date Country
2012204526 Sep 2016 AU
2856202 May 2013 CA
2864473 May 2013 CA
2823592 Nov 2021 CA
101227940 Jul 2008 CN
103263727 Aug 2013 CN
104307098 Jan 2015 CN
0630987 Dec 1994 EP
2130326 Dec 2009 EP
2141851 Jan 2010 EP
2160127 Mar 2010 EP
2178319 Apr 2010 EP
2192897 Jun 2010 EP
2226114 Sep 2010 EP
2258496 Dec 2010 EP
2361631 Aug 2011 EP
2368401 Sep 2011 EP
2387467 Nov 2011 EP
2396995 Dec 2011 EP
2397788 Dec 2011 EP
2445990 May 2012 EP
2471518 Jul 2012 EP
2475283 Jul 2012 EP
2486897 Aug 2012 EP
2626051 Aug 2013 EP
2628502 Aug 2013 EP
2661307 Nov 2013 EP
2688642 Jan 2014 EP
2810689 Dec 2014 EP
2810690 Dec 2014 EP
2868343 May 2015 EP
2966422 Jan 2016 EP
2968940 Jan 2016 EP
3184145 Jun 2017 EP
3323468 May 2018 EP
3328481 Jun 2018 EP
3527258 Aug 2019 EP
H0326620 Feb 1991 JP
3184145 Jul 2001 JP
2002200178 Jul 2002 JP
2004065529 Mar 2004 JP
2007526798 Sep 2007 JP
2008067917 Mar 2008 JP
2008543429 Dec 2008 JP
2014514043 Jun 2014 JP
2016506255 Mar 2016 JP
6132856 Apr 2017 JP
2017104685 Jun 2017 JP
2017525509 Sep 2017 JP
2018524113 Aug 2018 JP
2130326 May 1999 RU
2141851 Nov 1999 RU
2160127 Dec 2000 RU
2178319 Jan 2002 RU
2192897 Nov 2002 RU
2193441 Nov 2002 RU
2226114 Mar 2004 RU
2258496 Aug 2005 RU
2361631 Jul 2009 RU
2368401 Sep 2009 RU
2387467 Apr 2010 RU
2396995 Aug 2010 RU
2397788 Aug 2010 RU
2445990 Mar 2012 RU
2471518 Jan 2013 RU
2475283 Feb 2013 RU
2661307 Jul 2018 RU
97047357 Dec 1997 WO
02034331 May 2002 WO
02092165 Nov 2002 WO
03005887 Jan 2003 WO
03026735 Apr 2003 WO
03092795 Nov 2003 WO
2004087116 Oct 2004 WO
2005002663 Jan 2005 WO
2005051306 Jun 2005 WO
2005065768 Jul 2005 WO
2005087307 Sep 2005 WO
2006138069 Dec 2006 WO
2007007058 Jan 2007 WO
2007012114 Feb 2007 WO
2007047852 Apr 2007 WO
2007081764 Jul 2007 WO
2007107831 Sep 2007 WO
2008070807 Jun 2008 WO
2008075294 Jun 2008 WO
2008109862 Sep 2008 WO
2008121891 Oct 2008 WO
2009042217 Apr 2009 WO
2009111142 Sep 2009 WO
2010021977 Feb 2010 WO
2010055421 May 2010 WO
2010114998 Oct 2010 WO
2010124128 Oct 2010 WO
2011005607 Jan 2011 WO
2011136875 Nov 2011 WO
2012050200 Apr 2012 WO
2012075195 Jun 2012 WO
2012080964 Jun 2012 WO
2012094346 Jul 2012 WO
2012100260 Jul 2012 WO
2012129574 Sep 2012 WO
2013071307 May 2013 WO
2013071309 May 2013 WO
2013152124 Oct 2013 WO
2013179230 Dec 2013 WO
2013188965 Dec 2013 WO
2014005075 Jan 2014 WO
2014031142 Feb 2014 WO
2014089299 Jun 2014 WO
2014144785 Sep 2014 WO
2014149895 Sep 2014 WO
2014205356 Dec 2014 WO
2014209877 Dec 2014 WO
2015000800 Jan 2015 WO
2015048563 Apr 2015 WO
2015063127 May 2015 WO
2015106286 Jul 2015 WO
2016029159 Feb 2016 WO
2016033369 Mar 2016 WO
2016033372 Mar 2016 WO
2016064761 Apr 2016 WO
2016110804 Jul 2016 WO
2016112398 Jul 2016 WO
2016172239 Oct 2016 WO
2017011410 Jan 2017 WO
2017024276 Feb 2017 WO
2017035512 Mar 2017 WO
2017044904 Mar 2017 WO
2017058913 Apr 2017 WO
2017062508 Apr 2017 WO
2017117450 Jul 2017 WO
2017146659 Aug 2017 WO
2018039296 Mar 2018 WO
2018106843 Jun 2018 WO
2018160531 Aug 2018 WO
2018217791 Nov 2018 WO
2019211314 Nov 2019 WO
2020041502 Feb 2020 WO
2020041633 Feb 2020 WO
2020236946 Nov 2020 WO
Non-Patent Literature Citations (142)
Entry
Anderson, K., “Targeting Recovery: Priorities of the Spinal Cord-Injured Population,” Journal of Neurotrauma, vol. 21, No. 10, Oct. 2004, 13 pages.
Krassioukov, A. et al., “A Systematic Review of the Management of Autonomic Dysreflexia Following Spinal Cord Injury,” Archives of Physical Medicine and Rehabilitation, vol. 90, No. 4, Apr. 2009, 27 pages.
Krassioukov, A. et al., “A Systematic Review of the Management of Orthostatic Hypotension Following Spinal Cord Injury,” Archives of Physical Medicine and Rehabilitation, vol. 90, No. 5, May 2009, 22 pages.
Wan, D. et al., “Life-threatening outcomes associated with autonomic dysreflexia: A clinical review,” Journal of Spinal Cord Medicine, vol. 37, No. 1, Jan. 2014, 9 pages.
Phillips, A. et al., “Perturbed and spontaneous regional cerebral blood flow responses to changes in blood pressure after high-level spinal cord injury: the effect of midodrine,” Journal of Applied Physiology, vol. 116, No. 6, Mar. 15, 2014, Available Online Jan. 16, 2014, 20 pages.
Phillips, A. et al., “Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride,” Journal of Cerebral Blood Flow & Metabolism, vol. 34, No. 5, May 2014, 8 pages.
Phillips, A. et al., “Contemporary Cardiovascular Concerns after Spinal Cord Injury: Mechanisms, Maladaptations, and Management,” Journal of Neurotrama, vol. 32, No. 24, Dec. 15, 2015, 17 pages.
Robbins, H., “Some Aspects of the Sequential Design of Experiments,” Bulletin of the American Mathematical Society, vol. 58, Sep. 1, 1952, 9 pages.
Minoux, M., “Accelerated greedy algorithms for maximizing submodular set functions,” Optimization Techniques, Proceedings of the LNCIS, vol. 7, 1978, 10 pages.
Gittins, J. C., “Bandit Processes and Dynamic Allocation Indices,” Journal of the Royal Statistical Society B, vol. 41, No. 2, Jan. 1979, 17 pages.
Harrison, P. et al., “Individual Excitatory Post-Synaptic Potentials Due to Muscle Spindle la Afferents in Cat Triceps Surae Motoneurones,” The Journal of Physiology, vol. 312, No. 1, Mar. 1981, 16 pages.
Lovely, R. et al., “Effects of Training on the Recovery of Full-Weight-Bearing Stepping in the Adult Spinal Cat,” Experimental Neurology, vol. 92, No. 2, May 1986, 15 pages.
Barbeau, H. et al., “Recovery of locomotion after chronic spinalization in the adult cat,” Brain Research, vol. 412, No. 1, May 26, 1987, 12 pages.
Colgate, E. et al., “An Analysis of Contact Instability in Terms of Passive Physical Equivalents,” Proceedings of the 1989 IEEE International Conference on Robotics and Automation, Scottsdale, Arizona, May 14, 1989, 6 pages.
Wernig, A. et al., “Laufband locomotion with body weight support improved walking in persons with severe spinal cord injuries,” Paraplegia, vol. 30, No. 4, Apr. 1992, 10 pages.
Pratt, J. et al., “Series elastic actuators for high fidelity force control,” Industrial Robot: An International Journal, vol. 29, No. 3, Available as Early as Jan. 1, 2002, 13 pages.
Winter, D. A. et al., “An integrated EMG/biomechanical model of upper body balance and posture during human gait,” Progress in Brain Research, vol. 97, Ch. 32, Available as Early as Jan. 1, 1993, 9 pages.
Pratt, G. et al., “Stiffness Isn't Everything,” Proceedings of the Fourth International Symposium on Experimental Robotics, Jun. 30, 1995, Stanford, California, 6 pages.
Basso, D. et al., “MASCIS Evaluation of Open Field Locomotor Scores: Effects of Experience and Teamwork on Reliability,” Journal of Neurotrauma, vol. 13, No. 7, Jul. 1996, 17 pages.
Harkema, S. et al., “Human Lumbosacral Spinal Cord Interprets Loading During Stepping,” Journal of Neurophysiology, vol. 77, No. 2, Feb. 1, 1997, 15 pages.
Brosamle, C. et al., “Cells of Origin, Course, and Termination Patterns of the Ventral, Uncrossed Component of the Mature Rat Corticospinal Tract,” The Journal of Comparative Neurology, vol. 386, No. 2, Sep. 22, 1997, 11 pages.
Jones, D. R. et al., “Efficient Global Optimization of Expensive Black-Box Functions,” Journal of Global Optimization, vol. 13, 1998, 38 pages.
Dimitrijevic, M. M. et al., “Evidence for a Spinal Central Pattern Generator in Humans,” Annals New York Academy Sciences, vol. 860, 1998, 17 pages.
Kakulas, B., “A Review of the Neuropathology of Human Spinal Cord Injury with Emphasis on Special Features,” Proceedings of the Donald Munro Memorial Lecture at the American Paraplegia Society 44th Annual Conference, Sep. 9, 1998, Las Vegas, Nevada, 6 pages.
Hashtrudi-Zaad, K. et al., “On the Use of Local Force Feedback for Transparent Teleoperation,” Proceedings of the 1999 IEEE International Conference on Robotics and Automation, May 10, 1999, Detroit, Michigan, 7 pages.
Kirkwood, P., “Neuronal Control of Locomotion: From Mollusk to Man—G.N. Orlovsky, T.G. Deliagina and S. Grillner, Oxford University Press,” Clinical Neurophysiology, vol. 111, No. 8, Published Online Jul. 17, 2000, Aug. 1, 2000, 2 pages.
Murg, M. et al., “Epidural electric stimulation of posterior structures of the human lumbar spinal cord: 1. Muscle twitches—a functional method to define the site of stimulation.” Spinal Cord, vol. 38, 2000, 9 pages.
Auer, P. et al., “Finite-time Analysis of the Multiarmed Bandit Problem,” Machine Learning, vol. 47, No. 2, 2002, 22 pages.
Auer, P. “Using Confidence Bounds for Exploitation-Exploration Trade-offs,” Journal of Machine Learning Research, vol. 3, 2002, 26 pages.
Dimitrijevic, M. et al., “Clinical Elements for the Neuromuscular Stimulation and Functional Electrical Stimulation protocols in the Practice of Neurorehabilitation,” Artificial Organs, vol. 26, No. 3, 2002, 4 pages.
Gerasimenko, Y. et al., “Control of Locomotor Activity in Humans and Animals in the Absence of Supraspinal Influences,” Neuroscience and Behavioral Physiology, vol. 32, No. 4, 2002, 7 pages.
Herman, R. et al., “Spinal cord stimulation facilitates functional walking in a chronic, incomplete spinal cord injured,” Spinal Cord, vol. 40, No. 2, 2002, 4 pages.
Yakovenko, S. et al., “Spatiotemporal Activation of Lumbosacral Motoneurons in the Locomotor Step Cycle,” Journal of Neurophysiology, vol. 87, No. 3, Mar. 2002, 12 pages.
Ivanenko, Y. P. et al., “Temporal Components of the Motor Patterns Expressed by the Human Spinal Cord Reflect Foot Kinematics,” Journal of Neurophysiology, vol. 90, No. 5, Nov. 2003, Published Online Jul. 9, 2003, 11 pages.
Steward, O. et al., “False Resurrections: Distinguishing Regenerated from Spared Axons in the Injured Central Nervous System,” The Journal of Comparative Neurology, vol. 459, No. 1, Apr. 21, 2003, 8 pages.
Minassian, K. et al., “Stepping-like movements in humans with complete spinal cord injury induced by epidural stimulation of the lumbar cord: electromyographic study of compound muscle action potentials”, Spinal Cord, vol. 42, 2004, 16 pages.
Pearson, K., “Generating the walking gait: role of sensory feedback,” Progress in Brain Research, vol. 143, Chapter 12, Published Online Nov. 28, 2003, 2004, 7 pages.
Rasmussen, C., “Gaussian Processes in Machine Learning”, L.N.A.I., vol. 3176, 2003, 9 pages.
Carhart, M. et al., “Epidural Spinal-Cord Stimulation Facilitates Recovery of Functional Walking Following Incomplete Spinal-Cord Injury,” IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 12, No. 1, Mar. 15, 2004, 11 pages.
Bareyre, F. et al., “The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats,” Nature Neuroscience, vol. 7, No. 3, Published Online Feb. 15, 2004, Mar. 2004, 9 pages.
Dimitrijevic, M. et al., “Electrophysiological characteristics of H-reflexes elicited by percutaneous stimulation of the cauda equina,” Abstract No. 4927, Proceedings of the 34th Annual Meeting of the Society for Neuroscience, San Diego, California, 2004, 1 page.
Jilge, B. et al., “Initiating extension of the lower limbs in subjects with complete spinal cord injury by epidural lumbar cord stimulation,” Experimental Brain Research, vol. 154, 2004, 19 pages.
Ganley, K. et al., “Epidural Spinal Cord Stimulation Improves Locomotor Performance in Low ASIA C, Wheelchair-Dependent, Spinal Cord-Injured Individuals: Insights from Metabolic Response,” Topics in Spinal Cord Injury Rehabilitation, vol. 11, No. 2, 2005, 14 pages.
Krause, A. et al., “Near-optimal Nonmyopic Value of Information in Graphical Models,” Proceedings of the Twenty-First Conference on Uncertainty in Artificial Intelligence (UAI'05), 2005, Edinburgh, Scotland, 8 pages.
Minassian, K. et al., “Peripheral and central afferent input to the lumbar cord,” Biocybemetics and Biomedical Engineering, vol. 25, No. 3, 2005, 19 pages.
Liu, J. et al., “Stimulation of the Parapyramidal Region of the Neonatal Rat Brain Stem Produces Locomotor-Like Activity Involving Spinal 5-HT7 and 5-HT2A Receptors,” Journal of Neurophysiology, vol. 94, No. 2, Published Online May 4, 2005, Aug. 1, 2005, 13 pages.
Timozyk, W. et al., “Hindlimb loading determines stepping quantity and quality following spinal cord transection,” Brain Research, vol. 1050, No. 1-2, Published Online Jun. 24, 2005, Jul. 19, 2005, 10 pages.
Wernig, A., “Ineffectiveness▪ of Automated Locomotor Training,” Archives of Physical Medicine and Rehabilitation, vol. 86, No. 12, Dec. 2005, 2 pages.
Nessler, J. et al., “A Robotic Device for Studying Rodent Locomotion After Spinal Cord Injury,” IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 13, No. 4, Dec. 12, 2005, 10 pages.
Rasmussen, C. et al., “Gaussian Processes for Machine Learning,” The MIT Press, Cambridge, Massachusetts, 2006, 266 pages.
Pudo, D. et al., “Estimating Intensity Fluctuations in High Repetition Rate Pulse Trains Generated Using the Temporal Talbot Effect,” IEEE Photonics Technology Letters, vol. 18, No. 5, Mar. 1, 2006, 3 pages.
Reinkensmeyer, D. et al., “Tools for understanding and optimizing robotic gait training,” Journal of Rehabilitation Research & Development, vol. 43, No. 5, Aug. 2006, 14 pages.
Frey, M. et al., “A Novel Mechatronic Body Weight Support System,” IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 14, No. 3, Sep. 18, 2006, 11 pages.
Kocsis, L. et al. “Bandit Based Monte-Carlo Planning,” Proceedings of the European Conference on Machine Learning, Springer, Berlin, Heidelberg, Sep. 2006, 12 pages.
Fleshman, J. et al., “Electronic Architecture of Type-Identified a-Motoneurons in the Cat Spinal Cord,” Journal of Neurophysiology, vol. 60, No. 1, Jul. 1, 1988, 26 pages.
Jones, K. et al., “Computer Simulation of the Responses of Human Motoneurons to Composite 1A EPSPS: Effects of Background Firing Rate,” The Journal of Physiology, vol. 77, No. 1, 1997, 16 pages.
Hines, M. et al., “The Neuron Simulation Environment,” Neural Computation, vol. 9, No. 6, Aug. 15, 1997, 26 pages.
Prochazka, A. et al., “Ensemble firing of muscle afferents recorded during normal locomotion in cats,” The Journal of Physiology, vol. 507, No. 1, Feb. 15, 1998, 12 pages.
Prochazka, A. et al., “Models of ensemble filing of muscle spindle afferents recorded during normal locomotion in cats,” The Journal of Physiology, vol. 507, No. 1, Feb. 15, 1998, 15 pages.
Rattay, F. et al., “Epidural electrical stimulation of posterior structures of the human lumbosacral cord: 2. Quantitative analysis by computer modeling,” Spinal Cord, vol. 38, 2000, 17 pages.
Mcintyre, C. et al., “Modeling the Excitability of Mammalian Nerve Fibers: Influence of Afterpotentials on the Recovery Cycle,” Journal of Neurophysiology, vol. 87, No. 2, Feb. 2002, 12 pages.
Minassian, K. et al., “Human lumbar cord circuitries can be activated by extrinsic tonic input to generate locomotor-like activity,” Human Movement Science, vol. 26, No. 2, 2007, 21 pages.
Rodger, D. et al., “High Density Flexible Parylene-Based Multielectrode Arrays for Retinal and Spinal Cord Stimulation,” Proceedings of the 14th International Conference on Solid-State Sensors, Actuators and Microsystems, 2007, pp. 4 pages.
Stienen, A. et al., “Analysis of reflex modulation with a biologically realistic neural network,” Journal of Computer Neuroscience, vol. 23, No. 3, Dec. 2007, Available Online May 15, 2007, 16 pages.
Johnson, W. et al., “Application of a Rat Hindlimb Model: A Prediction of Force Spaces Reachable Through Stimulation of Nerve Fascicles,” IEEE Transactions on Bio-Medical Engineering, vol. 58, No. 12, Dec. 2011, Available Online Jan. 17, 2011, 22 pages.
Van Den Brand, R. et al., “Restoring Voluntary Control of Locomotion after Paralyzing Spinal Cord Injury,” Science Magazine, vol. 336, No. 6085, Jun. 1, 2012, 5 pages.
Hennig, P. et al., “Entropy search for information-efficient global optimization,” Journal of Machine Learning Research (JMLR), vol. 13, Jun. 2012, 29 pages.
Gilja, V. et al., “A high-performance neural prosthesis enabled by control algorithm design,” Nature Neuroscience, vol. 15, No. 12, Dec. 2012, Published Online Nov. 18, 2012, 56 pages.
Minassian, K. et al., “Neuromodulation of lower limb motor control in restorative neurology,” Clinical Neurology and Neurosurgery, vol. 114, 2012, 9 pages.pp. 489-497.
Ryzhov, I. et al., “The knowledge gradient algorithm for a general class of online learning problems,” Operations Research, vol. 60, No. 1, 2012, 47 pages.
Azimi, J. et al., “Hybrid Batch Bayesian Optimization,” Proceedings of the 29th International Conference on Machine Learning, 2012, Edinburgh, Scotland, 12 pages.
Azimi, J. et al., “Batch Active Learning via Coordinated Matching,” Proceedings of the 29th International Conference on Machine Learning, 2012, Edinburgh, Scotland, 8 pages.
Lozano, A. et al., “Probing and Regulating Dysfunctional Circuits Using Deep Brain Stimulation,” Neuron, vol. 77, No. 3, Feb. 6, 2013, 19 pages.
Minassian et al., “Mechanisms of rhythm generation of the human lumbar spinal cord in repose to tonic stimulation without and with step-related sensory feedback,” Biomedizinische Technik, vol. 58, (Suppl. 1), 2013, 3 pages.
Capogrosso, M. et al., “A Computational Model for Epidural Electrical Stimulation of Spinal Sensorimotor Circuits”, Journal of Neuroscience, vol. 33, No. 49, Dec. 4, 2013, 15 pages.
Sayenko, D. et al., “Neuromodulation of evoked muscle potentials induced by epidural spinal-cord stimulation in paralyzed individuals,” Journal of Neurophysiology, vol. 111, No. 5, 2014, Published Online Dec. 11, 2013, 12 pages.
Hofstoetter, U. et al., “Effects of transcutaneous spinal cord stimulation on voluntary locomotor activity in an incomplete spinal cord injured individual,” Biomed Tech, vol. 58 (Suppl. 1), 2013, 3 pages.
Nandra, M. et al., “Microelectrode Implants for Spindal Cord Stimulation in Rats,” Doctor of Philosophy Thesis, California Institute of Technology, 2014, 104 pages.
Angeli, C. et al., “Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans,” Brain, vol. 137, No. 5, May 2014, Available Online Apr. 8, 2014, 16 pages.
Zhang, T. et al., “Mechanisms and models of spinal cord stimulation for the treatment of neuropathic pain,” Brain Research, vol. 1569, Jun. 20, 2014, Published Online May 4, 2014, 14 pages.
Wenger, N. et al. “Closed-loop neuromodulation of spinal sensorimotor circuits controls refined locomotion after complete spinal cord injury,” Science Translational Medicine, Sep. 24, 2014, vol. 6, No. 255, 10 pages.
Wenger, N. et al., “Supplementary Materials for Closed-loop neuromodulation of spinal sensorimotor circuits controls refined locomotion after complete spinal cord injury,” Science Translational Medicine, vol. 6, No. 255, Sep. 24, 2014, 14 pages.
Takeoka, A. et al., “Muscle Spindle Feedback Directs Locomotor Recovery and Circuit Reorganization after Spinal Cord Injury,” Cell, vol. 159, No. 7, Dec. 18, 2014, 27 pages.
Hofstoetter, U. et al., “Modification of spasticity by transcutaneous spinal cord stimulation in individuals with incomplete spinal cord injury,” The Journal of Spinal Cord Medicine, vol. 37, No. 2, 2014, 10 pages.
Minev, I. et al., “Electronic dura mater for long-term multimodal neural interfaces,” Science Magazine, vol. 347, No. 6218, Jan. 9, 2015, 64 pages.
Gerasimenko, Y. et al., “Noninvasive Reactivation of Motor Descending Control after Paralysis,” Journal of Neurotrauma, vol. 32, 2015, 13 pages.
Danner, S. et al., “Human spinal locomotor control is based on flexibly organized burst generators,” Brain, vol. 138, No. 3, Mar. 2015, Available Online Jan. 12, 2015, 12 pages.
Rejc, E. et al., “Effects of Lumbosacral Spinal Cord Epidural Stimulation for Standing after Chronic Complete Paralysis in Humans,” PLoS One, vol. 10, No. 7, Jul. 24, 2015, 20 pages.
Shamir, R. et al., “Machine Learning Approach to Optimizing Combined Stimulation and Medication Therapies for Parkinson's Disease,” Brain Stimulation, vol. 8, No. 6, Nov. 2015, Published Online Jun. 15, 2015, 22 pages.
Jarosiewicz, B. et al., “Virtual typing by people with tetraplegia using a self-calibrating intracortical brain-computer interface,” Science Translational Medicine, vol. 7, No. 313, Nov. 11, 2015, 11 pages.
Jarosiewicz, B. et al., “Supplementary Materials for Virtual typing by people with tetraplegia using a self-calibrating intracortical brain-computer interface,” Science Translational Medicine, vol. 7, No. 313, Nov. 11, 2015, 26 pages.
Moraud, E. et al., “Mechanisms Underlying the Neuromodulation of Spinal Circuits for Correcting Gait and Balance Deficits after Spinal Cord Injury,” Neuron, vol. 89, No. 4, Feb. 17, 2016, Published Online Feb. 4, 2016, 15 pages.
Danner, S. M. et al., “Body Position Influences Which neural structures are recruited by lumbar transcutaneous spinal cord stimulation”, PLoS One, vol. 11, No. 1, 2016, 13 pages.
Burke, R., “Group la Synaptic Input to Fast and Slow Twitch Motor Units of Cat Triceps Surae,” The Journal of Physiology, vol. 196, vol. 3, Jun. 1, 1968, 26 pages.
Cai, L. et al., “Implications of Assist-As-Needed Robotic Step Training after a Complete Spinal Cord Injury on Intrinsic Strategies of Motor Learning,” The Journal of Neuroscience, vol. 26, No. 41, Oct. 11, 2006, 5 pages.
Courtine, G. et al., “Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?,” Nature Medicine, vol. 13, No. 5, May 2007, 13 pages.
Drew, T. et al., “Cortical mechanisms involved in visuomotor coordination during precision walking,” Brain Research Reviews, vol. 57, No. 1, Jan. 2007, Published Online Aug. 22, 2007, 13 pages.
Edgerton, V. et al., “Training Locomotor Networks,” Brain Research Reviews, vol. 57, Jan. 2008, Published Online Sep. 16, 2007, 25 pages.
Kwakkel, G. et al., “Effects of Robot-assisted therapy on upper limb recovery after stroke: A Systematic Review,” Neurorehabilitation and Neural Repair, vol. 22, No. 2, Mar. 2008, Published Online Sep. 17, 2007, 17 pages.
Lizotte, D. et al., “Automatic gait optimization with Gaussian process regression,” Proceedings of the 20th international joint conference on Artifical intelligence (IJCAI), Jan. 6, 2007, Hyderabad, India, 6 pages.
Courtine, G. et al., “Recovery of supraspinal control of stepping via indirect propriospinal relay connections after spinal cord injury,” Nature Medicine, vol. 14, No. 1, Jan. 6, 2008, 6 pages.
Cowley, K. et al., “Propriospinal neurons are sufficient for bulbospinal transmission of the locomotor command signal in the neonatal rat spinal cord,” The Journal of Physiology, vol. 586, No. 6, Mar. 15, 2008, Published Online Jan. 31, 2008, 13 pages.
Krause, A. et al. “Near-Optimal Sensor Placements in Gaussian Processes: Theory, Efficient Algorithms and Empirical Studies,” Journal of Machine Learning Research (JMLR), vol. 9, Feb. 2008, 8 pages.
Lavrov, I. et al., “Epidural Stimulation Induced Modulation of Spinal Locomotor Networks in Adult Spinal Rats,” Journal of Neuroscience, vol. 28, No. 23, Jun. 4, 2008, 8 pages.
Vallery, H. et al., “Compliant Actuation of Rehabilitation Robots,” IEEE Robotics & Automation Magazine, vol. 15, No. 3, Sep. 12, 2008, 10 pages.
Abernethy, J. et al., “Competing in the Dark: An Efficient Algorithm for Bandit Linear Optimization,” Conference on Learning Theory, 2008, 13 pages.
Bubeck, S. et al., “Online Optimization in X-Armed Bandits,” Advances in Neural Information Processing Systems (NIPS), 2008, 8 pages.
Ward, A. R., “Electrical Stimulation Using Kilohertz-Frequency Alternating Current,” Physical Therapy, vol. 89, 2009, Published online Dec. 18, 2008, 10 pages.
Dani, V. et al., “Stochastic Linear Optimization Under Bandit Feedback,” Proceedings of the 21st Annual Conference on Learning Theory (COLT), 2008, Helsinki, Finland, 15 pages.
Edgerton, V. et al., “Robotic Training and Spinal Cord Plasticity,” Brain Research Bulletin, vol. 78, No. 1, Jan. 15, 2009, Published Online Nov. 14, 2008, 19 pages.
Hofstoetter, U. et al., “Modification of Reflex Responses to Lumbar Posterior Root Stimulation by Motor Tasks in Healthy Subjects,” Artificial Organs, vol. 32, No. 8, 2008, 5 pages.
Kleinberg, R. et al., “Multi-armed bandits in metric spaces,” Proceedings of the STOC, Computer and Automation Research Institute of the Hungarian Academy of Sciences, Budapest, Hungary, 2008, 26 pages.
Brochu, E. et al., “A Tutorial on Bayesian Optimization of Expensive Cost Functions, with Application to Active User Modeling and Hierarchical Reinforcement Learning,” TR-2009-23, UBC, 2009, 49 pages.
Bubeck, S. et al., “Pure Exploration in Finitely-Armed and Continuous-Armed Bandits problems,” ALT, 2009, 35 pages.
Fuentes, R. et al., “Spinal Cord Stimulation Restores Locomotion in Animal Models of Parkinson's Disease,” Science, vol. 323, No. 5921, Mar. 20, 2009, 14 pages.
Hofstoetter, U. et al., “Model of spinal cord reflex circuits in humans: Stimulation frequency-dependence of segmental activities and their interactions,” Proceedings of the Second Congress International Society of Intraoperative Neurophysiology (ISIN), Dubrovnik, Croatia, 2009, 149 pages.
Courtine, G. et al., “Transformation of nonfunctional spinal circuits into functional states after the loss of brain input,” Nature Neuroscience, vol. 12, No. 10, Oct. 2009, Published Online Sep. 20, 2009, 12 pages.
Minassian, K. et al., “Posterior root-muscle reflex,” Proceedings of the Second Congress International Society of Intraoperative Neurophysiology (ISIN), Dubrovnik, Croatia, 2009, 6 pages.
Musienko, P. et al., “Combinatory Electrical and Pharmacological Neuroprosthetic Interfaces to Regain Motor Function After Spinal Cord Injury,” IEEE Transactions on Biomedical Engineering, vol. 56, No. 11, Nov. 2009, Published Online Jul. 24, 2009, 5 pages.
Alto, L. et al., “Chemotropic Guidance Facilitates Axonal Regeneration and Synapse Formation after Spinal Cord Injury,” Nature Neuroscience, vol. 12, No. 9, Sep. 2009, Published Online Aug. 2, 2009, 22 pages.
Azimi, J. et al., “Batch Bayesian Optimization via Simulation Matching,” Proceedings of the Advances in Neural Information Processing Systems (NIPS), 2010, Vancouver, British Columbia, Canada, 9 pages.
Hagglund, M. et al., “Activation of groups of excitatory neurons in the mammalian spinal cord or hindbrain evokes locomotion,” Nature Neuroscience, vol. 13, No. 2, Feb. 2010, Published Online Jan. 17, 2010, 8 pages.
Wessels, M. et al., “Body Weight-Supported Gait Training for Restoration of Walking in People with an Incomplete Spinal Cord Injury: A Systematic Review,” Journal of Rehabilitation Medicine, vol. 42, No. 6, Jun. 2010, 7 pages.
Duschau-Wicke, A. et al., “Patient-cooperative control increases active participation of individuals with SCI during robot-aided gait training,” Journal of NeuroEngineering and Rehabilitation, vol. 7, No. 43, Sep. 10, 2010, 13 pages.
Ladenbauer, J. et al., “Stimulation of the human lumbar spinal cord with implanted and surface electrodes: a computer simulation study,” IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 18, No. 6, 2010, 9 pages.
Minassian, K. et al., “Transcutaneous stimulation of the human lumbar spinal cord: Facilitating locomotor output in spinal cord injury,” Proceedings of the Society for Neuroscience, Conference Proceedings, Neuroscience 2010, San Diego, CA, Abstract Viewer/ Itinerary Planner No. 286. 19, Abstract & Poster Attached, 2010, 1 page.
Rasmussen, C. E. et al., “Gaussian Processes for Machine Learning (GPML) Toolbox,” The Journal of Machine Learning Research, vol. 11, 2010, 9 pages.
Widmer, C. et al., “Inferring latent task structure for multitask learning by multiple kernel learning,” BMC Bioinformatics, vol. 11, Suppl 8:S5, 2010, 8 pages.
Rosenzweig, E. et al., “Extensive Spontaneous Plasticity of Corticospinal Projections After Primate Spinal Cord Injury,” Nature Neuroscience, vol. 13, No. 12, Dec. 2010, Published Online Nov. 14, 2010, 19 pages.
Srinivas, N. et al., “Gaussian process optimization in the bandit setting: No. regret and experimental design,” Proceedings of the 27th International Conference on Machine Learning, 2010, Haifa, Israel, 17 pages.
Tenne, Y. et al., “Computational Intelligence in Expensive Optimization Problems,” Adaptation, Learning, and Optimization, vol. 2, Springer, Berlin Heidelberg, 2010, 32 pages.
Zorner, B. et al., “Profiling locomotor recovery: comprehensive quantification of impairments after CNS damage in rodents,” Nature Methods, vol. 7, No. 9, Sep. 2010, Published Online Aug. 15, 2010, 11 pages.
Ada, L. et al., “Mechanically assisted walking with body weight support results in more independent walking than assisted overground walking in non-ambulatory patients early after stroke: a systematic review,” Journal of Physiotherapy, vol. 56, No. 3, Sep. 2010, 9 pages.
Hidler, J. et al., “ZeroG: Overground gait and balance training system,” Journal of Rehabilitation Research & Development, vol. 48, No. 4, Available as Early as Jan. 1, 2011, 12 pages.
Harkema, S. et al., “Effect of Epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study,” Lancet, vol. 377, No. 9781, Jun. 4, 2011, Available Online May 19, 2011, 17 pages.
Krause, A. et al. “Contextual Gaussian Process Bandit Optimization”, In Advances in Neural Information Processing Systems (NIPS), 2011, 9 pages.
Musselman, K. et al., “Spinal Cord Injury Functional Ambulation Profile: A New Measure of Walking Ability,” Neurorehabilitation and Neural Repair, vol. 25, No. 3, Published Online Feb. 25, 2011, (Mar. 2011), 9 pages.
Wirz, M. et al., “Effectiveness of automated locomotor training in patients with acute incomplete spinal cord injury: A randomized controlled multicenter trial,” BMC Neurology, vol. 11, No. 60, May 27, 2011, 9 pages.
Musienko, P. et al., “Controlling specific locomotor behaviors through multidimensional monoaminergic modulation of spinal circuitries,” The Journal of Neuroscience, vol. 31, No. 25, Jun. 22, 2011, 32 pages.
Musienko, P. et al. “Multi-system neurorehabilitative strategies to restore motor functions following severe spinal cord injury,” Experimental Neurology, vol. 235, No. 1, Published Online Sep. 7, 2011, (May 2012), 10 pages.
Nandra, M. S. et al., “A parylene-based microelectrode array implant for spinal cord stimulation in rats,” Proceedings of the IEEE Engineering in Medicine and Biology Society, 2011, Boston, Massachusetts, 13 pages.
Sun, F. et al., “Sustained axon regeneration induced by co-deletion of PTEN and SOCS3,” Nature, vol. 480, No. 7377, Dec. 15, 2011, Published Online Nov. 6, 2011, 12 pages.
Related Publications (1)
Number Date Country
20220111208 A1 Apr 2022 US
Provisional Applications (3)
Number Date Country
62581305 Nov 2017 US
62470468 Mar 2017 US
62460224 Feb 2017 US
Continuations (1)
Number Date Country
Parent 16486788 US
Child 17644765 US